BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
Number Citing Articles
1 Berger KL, Scherer J, Ranga M, Sha N, Stern JO, Quinson AM, Kukolj G. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. Antimicrob Agents Chemother 2015;59:6017-25. [PMID: 26195509 DOI: 10.1128/AAC.00932-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
2 Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015;9:6083-6094. [PMID: 26622169 DOI: 10.2147/DDDT. S80226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ghazaryan L, Smith L, Parker M, Flanigan C, Pulver W, Sullivan T, Carrascal A. Hepatitis C Seroprevalence Among HIV-Infected Childbearing Women in New York State in 2006. Matern Child Health J 2016;20:550-5. [PMID: 26520159 DOI: 10.1007/s10995-015-1853-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ogawa E, Furusyo N, Nomura H, Takahashi K, Higashi N, Kawano A, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res. 2016;136:37-44. [PMID: 27789224 DOI: 10.1016/j.antiviral.2016.10.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
5 Roche B, Coilly A, Roque-Afonso AM, Samuel D. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses 2015;7:5155-68. [PMID: 26404355 DOI: 10.3390/v7092864] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
6 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
7 Elzorkany K, Kora MA, Wahed ASA, Zaghla HE, Zahran AM, Yassein YS, El Naggar AZ, Essa A, Gadallah AA. Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals. Int J Nephrol Renovasc Dis 2020;13:351-8. [PMID: 33273842 DOI: 10.2147/IJNRD.S275721] [Reference Citation Analysis]
8 Nguyen NH, Yee BE, Chang C, Jin M, Lutchman G, Lim JK, Nguyen MH. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol 2016;3:e000066. [PMID: 26966549 DOI: 10.1136/bmjgast-2015-000066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yoo J, Lee JM, Joo I, Yoon JH. Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography. 2020;39:52-59. [PMID: 31623416 DOI: 10.14366/usg.19013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
10 d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and HepaIcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One 2017;12:e0177402. [PMID: 28520749 DOI: 10.1371/journal.pone.0177402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Okubo T, Atsukawa M, Tsubota A, Shimada N, Abe H, Yoshizawa K, Arai T, Nakagawa A, Itokawa N, Kondo C. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants. Hepatol Res. 2017;47:641-649. [PMID: 27487797 DOI: 10.1111/hepr.12784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Crowley D, Murtagh R, Cullen W, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, O'Connor E, O'Reilly D, Betts-Symonds G, Tobin C, Van Hout MC, Lambert JS. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. Harm Reduct J. 2019;16:42. [PMID: 31277665 DOI: 10.1186/s12954-019-0313-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
13 Mayberry J, Lee WM. The Revolution in Treatment of Hepatitis C. Medical Clinics of North America 2019;103:43-55. [DOI: 10.1016/j.mcna.2018.08.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS. Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping. Diagn Microbiol Infect Dis 2019;94:344-8. [PMID: 30975461 DOI: 10.1016/j.diagmicrobio.2019.02.020] [Reference Citation Analysis]
15 Hu KQ, Cui W. Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection. Dig Dis Sci 2018;63:1237-42. [PMID: 29516328 DOI: 10.1007/s10620-018-4968-9] [Reference Citation Analysis]
16 Santana-Salgado I, Bautista-Santos A, Moreno-Alcántar R. Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals. Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(22)00025-1. [PMID: 35523684 DOI: 10.1016/j.rgmxen.2021.09.005] [Reference Citation Analysis]
17 Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus 2016;5:1365. [PMID: 27588258 DOI: 10.1186/s40064-016-2920-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. J Med Virol 2018;90:1087-93. [PMID: 29427443 DOI: 10.1002/jmv.25047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Satapathy SK, Joglekar K, Molnar MZ, Ali B, Gonzalez HC, Vanatta JM, Eason JD, Nair SP. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function. Liver Transpl 2018;24:1040-9. [PMID: 29573131 DOI: 10.1002/lt.25059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
20 Vicenti I, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. J Clin Virol 2016;76:20-3. [PMID: 26802683 DOI: 10.1016/j.jcv.2016.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Lee AB, Karumberia S, Gilmore A, Williams E, Bruner N, Overton ET, Saag MS, Franco RA. Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness. J Infect Dis 2020;222:S365-75. [PMID: 32877566 DOI: 10.1093/infdis/jiaa207] [Reference Citation Analysis]
22 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban J, Esteban R. Removal from liver transplantation list of a hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir. Transpl Infect Dis 2016;18:442-5. [DOI: 10.1111/tid.12538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Blanco JR, Rivero-Juarez A. HCV genotype 3: a wolf in sheep's clothing. Expert Rev Anti Infect Ther 2016;14:149-52. [PMID: 26635242 DOI: 10.1586/14787210.2016.1127757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
25 Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, Malhotra A, Parvez A, Sood A. Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. J Clin Exp Hepatol 2018;8:7-14. [PMID: 29743791 DOI: 10.1016/j.jceh.2017.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bonsall D, Black S, Howe AY, Chase R, Ingravallo P, Pak I, Brown A, Smith DA, Bowden R, Barnes E. Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. Infect Drug Resist 2018;11:1119-35. [PMID: 30127629 DOI: 10.2147/IDR.S156581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SS, Fouad MHA, Rizk FH, Khodeir SA, Abd-Elsalam S. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018;11:295-8. [PMID: 29535545 DOI: 10.2147/IDR.S153060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
28 Liu L, Nardo D, Li E, Wang GP. CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS 2016;30:691-700. [PMID: 26645605 DOI: 10.1097/QAD.0000000000000997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
29 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Curr HIV/AIDS Rep 2017;14:110-21. [PMID: 28432579 DOI: 10.1007/s11904-017-0358-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
30 Chen L, Du L, Kang S, Ma F, Li C, He M, Bai L, Tang H. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep 2021;11:11301. [PMID: 34050222 DOI: 10.1038/s41598-021-90706-5] [Reference Citation Analysis]
31 Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-Gómez M, Rodríguez FG, Pascasio JM, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2017;45:468-75. [PMID: 27896822 DOI: 10.1111/apt.13883] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
32 Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol. 2018;53:857-863. [PMID: 29779403 DOI: 10.1080/00365521.2018.1473486] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
33 Burke LA, Marks KM. Drugs to Treat Viral Hepatitis. Infectious Diseases. Elsevier; 2017. pp. 1327-1332.e1. [DOI: 10.1016/b978-0-7020-6285-8.00155-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Ueda Y, Ikegami T, Soyama A, Akamatsu N, Shinoda M, Ishiyama K, Honda M, Marubashi S, Okajima H, Yoshizumi T, Eguchi S, Kokudo N, Kitagawa Y, Ohdan H, Inomata Y, Nagano H, Shirabe K, Uemoto S, Maehara Y. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience: Simeprevir-based triple therapy after LDLT. Hepatol Res 2016;46:1285-93. [DOI: 10.1111/hepr.12684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
35 Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017;23:51-56. [PMID: 28297836 DOI: 10.3350/cmh.2016.0053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
36 Surendra M, Raju SB, Sridhar N, Vijay Kiran B, Rajesh G, Anvesh G, Raju N. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study. Hemodial Int 2018;22:217-21. [PMID: 28972699 DOI: 10.1111/hdi.12604] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
37 Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; Host-Directed Therapies Network consortium. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 2016;16:e47-63. [PMID: 27036359 DOI: 10.1016/S1473-3099(16)00078-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 107] [Article Influence: 27.0] [Reference Citation Analysis]
38 Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Freekh DA, Helmy MW, Said M, El-Khodary NM. The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection. Saudi Pharm J 2021;29:1120-8. [PMID: 34703365 DOI: 10.1016/j.jsps.2021.08.006] [Reference Citation Analysis]
40 Sinit RB, Dorer RK, Flores JP, Aboulafia DM. Rare Causes of Isolated and Progressive Splenic Lesions: Challenges in Differential Diagnosis, Evaluation, and Treatment of Primary Splenic Lymphomas. Clin Med Insights Blood Disord 2020;13:1179545X20926188. [PMID: 32565679 DOI: 10.1177/1179545X20926188] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chamorro-de-vega E, Gimenez-manzorro A, Rodriguez-gonzalez CG, Escudero-vilaplana V, Collado Borrell R, Ibañez-garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-pinto A, Manrique-rodriguez S, Fernandez-llamazares CM, Marzal-alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother 2016;50:901-8. [DOI: 10.1177/1060028016659306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
44 Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018;67:1253-60. [PMID: 29152781 DOI: 10.1002/hep.29671] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 22.0] [Reference Citation Analysis]
45 Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C, Marins EG, Paxinos EE, Marino E, Wedemeyer H, Sarrazin C, Kessler HH. Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. J Clin Microbiol 2017;55:1131-9. [PMID: 28122870 DOI: 10.1128/JCM.02193-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky J, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology 2018;3:125-33. [DOI: 10.1016/s2468-1253(17)30284-4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 35] [Article Influence: 22.3] [Reference Citation Analysis]
47 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
48 Liu H, Zhang T, Yan Y. Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis. Medicine (Baltimore) 2016;95:e5555. [PMID: 27930559 DOI: 10.1097/MD.0000000000005555] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:974-83. [PMID: 31357028 DOI: 10.1016/j.cgh.2019.07.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
50 Miotto N, Mendes LC, Zanaga LP, Lazarini MSK, Goncales ESL, Pedro MN, Goncales FL Jr, Stucchi RSB, Vigani AG. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13:e0199941. [PMID: 29990371 DOI: 10.1371/journal.pone.0199941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
51 Mucenic M, Brandão ABM, Marroni CA, Fleck Junior AM, Zanotelli ML, Leipnitz I, Meine MH, Kiss G, Martini J, Schlindwein ES, Costabeber AM, Sacco FKR, Rossato G, Cantisani GPC. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review. Rev Inst Med Trop Sao Paulo 2019;61:e12. [PMID: 30785566 DOI: 10.1590/S1678-9946201961012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-sobol H, Mo H, Brainard DM, Yang Y, Dao L, Wang G, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology 2019;4:127-34. [DOI: 10.1016/s2468-1253(18)30343-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 16.3] [Reference Citation Analysis]
53 Silva MJ, Pereira C, Loureiro R, Balsa C, Lopes P, Água-Doce I, Belo E, Martins HC, Coutinho R, Pádua E. Hepatitis C in a Mobile Low-Threshold Methadone Program. Eur J Gastroenterol Hepatol 2017;29:657-62. [PMID: 28151750 DOI: 10.1097/MEG.0000000000000843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. Hepatology 2016;64:1495-506. [PMID: 27531416 DOI: 10.1002/hep.28767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Hamad AE, Mohammed BS, Derayea SM, El-malla SF. Micelle sensitized synchronous spectrofluorimetric approaches for the simultaneous determination of simeprevir and ledipasvir: Application to pharmaceutical formulations and human plasma. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2020;239:118471. [DOI: 10.1016/j.saa.2020.118471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Masetti C, Lleo A, Colombo M, Colombo M, Aghemo A. Postsustained Virological Response Management in Hepatitis C Patients. Semin Liver Dis 2020;40:233-9. [PMID: 32107758 DOI: 10.1055/s-0040-1702944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst 2016;108. [PMID: 27075854 DOI: 10.1093/jnci/djw035] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
59 Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 27-38. e4. [PMID: 28479504 DOI: 10.1016/j.cgh.2017.04.038] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 15.4] [Reference Citation Analysis]
60 Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T. Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection. Hepatol Res 2019;49:512-20. [PMID: 30628746 DOI: 10.1111/hepr.13311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. J Formos Med Assoc 2016;115:440-4. [PMID: 26786212 DOI: 10.1016/j.jfma.2015.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
62 Yakoot M, Abdo AM, Yousry A, Helmy S. The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study. Drug Des Devel Ther 2015;9:6027-33. [PMID: 26628861 DOI: 10.2147/DDDT.S95499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
64 Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation 2017;101:2739-45. [PMID: 28795982 DOI: 10.1097/TP.0000000000001907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
65 Coppola N, Portunato F, Buonomo AR, Staiano L, Scotto R, Pinchera B, De Pascalis S, Amoruso DC, Martini S, Pisaturo M, Coppola C, Gentile I. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. J Nephrol 2019;32:763-73. [PMID: 30977055 DOI: 10.1007/s40620-019-00608-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
66 Valdez-Hernández P, Rodríguez-Aguilar EF, Páez-Zayas VM, Lizárraga-Gómez E, García-Juárez I. [Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system]. Salud Publica Mex 2018;60:738-40. [PMID: 30699280 DOI: 10.21149/9492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Calès P, Boursier J, Lebigot J, de Ledinghen V, Aubé C, Hubert I, Oberti F. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? Aliment Pharmacol Ther 2017;45:991-1003. [DOI: 10.1111/apt.13954] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
68 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Maan R, Al Marzooqi SH, Klair JS, Karkada J, Cerocchi O, Kowgier M, Harrell SM, Rhodes KD, Janssen HLA, Feld JJ, Duarte-Rojo A. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Aliment Pharmacol Ther 2017;46:46-55. [PMID: 28470850 DOI: 10.1111/apt.14117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
70 Guss D, Sherigar J, Mohanty SR. Management of Hepatitis C: A Practical Primer for Nurses. Gastroenterol Nurs 2020;43:22-7. [PMID: 31913958 DOI: 10.1097/SGA.0000000000000430] [Reference Citation Analysis]
71 Rosen HR. "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research? Hepatology 2017;65:341-9. [PMID: 27640881 DOI: 10.1002/hep.28848] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
72 Sadeghi A, Amiri R, Akbarpour E, Mirminachi B, Sharifi AH, Merat S. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct-acting antiviral therapy. Int J Clin Pract 2021;75:e14145. [PMID: 33709413 DOI: 10.1111/ijcp.14145] [Reference Citation Analysis]
73 Chan S, Isbel NM, Hawley CM, Campbell SB, Campbell KL, Morrison M, Francis RS, Playford EG, Johnson DW. Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. Medicina (Kaunas) 2019;55:E672. [PMID: 31590269 DOI: 10.3390/medicina55100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Intern Med 2018;57:1533-42. [PMID: 29321441 DOI: 10.2169/internalmedicine.9857-17] [Reference Citation Analysis]
75 Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 2019;71:666-72. [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
76 Batskikh SN, Vinnitskaya EV, Sandler YG, Khaimenova TY. [Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis]. Ter Arkh 2018;90:67-73. [PMID: 32598651 DOI: 10.26442/terarkh201890114-73] [Reference Citation Analysis]
77 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Naz Z, Wahid B, Usman S, Saleem K, Rafique S, Ali A, Idrees M. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. J Interferon Cytokine Res 2018;38:255-60. [PMID: 29920131 DOI: 10.1089/jir.2017.0138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
80 Rattay T, Dumont IP, Heinzow HS, Hutton DW. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers. Gastroenterology 2017;153:1531-1543.e2. [DOI: 10.1053/j.gastro.2017.10.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
81 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
82 Azeem HA, Alkabeer AM, Mohammed AS, Hussein AA. Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs). Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00121-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wahab MA, Shehta A, Elshoubary M, Yassen AM, Elmorshedi M, Salah T, Sultan AM, Fathy O, Elsarraf WR, Shiha U, Zalata K, Elghawalby AN, Eldesoky M, Monier A, Said R, Elsabagh AM, Ali M, Kandeel A, Abdalla U, Aboelella M, Elsadany M, Abdel-Khalek EE, Marwan A, ElMorsi FM, Adly R. Living-Donor Liver Transplantation in Hepatitis C Virus Era: A Report of 500 Consecutive Cases in a Single Center. Transplant Proc 2018;50:1396-406. [PMID: 29880362 DOI: 10.1016/j.transproceed.2018.02.085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
84 Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J, Lee K, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 2016;36:635-43. [DOI: 10.1089/jir.2015.0173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
85 Montes ML, Olveira A, Ahumada A, Aldámiz T, García-samaniego J, Clemente A, Berenguer J, González-garcía J, Martín-carbonero L. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 2017;31:1253-60. [DOI: 10.1097/qad.0000000000001465] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
86 Winetsky D, Zucker J, Slowikowski J, Scherer M, Verna EC, Gordon P. Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C? Open Forum Infect Dis 2019;6:ofz178. [PMID: 31123691 DOI: 10.1093/ofid/ofz178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis 2016;63:776-83. [PMID: 27325691 DOI: 10.1093/cid/ciw387] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
88 Poliwczak AR, Białkowska J, Woźny J, Koziróg M, Bała A, Jabłkowski M. Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C. Arch Med Sci 2020;16:1031-9. [PMID: 32863991 DOI: 10.5114/aoms.2020.96600] [Reference Citation Analysis]
89 Fisher RA. Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? Nat Rev Gastroenterol Hepatol. 2017;14:373-382. [PMID: 28196987 DOI: 10.1038/nrgastro.2017.2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
90 Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry-Roguet V, Tamalet C, Lacarelle B, Poizot-Martin I. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol 2018;84:404-9. [PMID: 29028125 DOI: 10.1111/bcp.13450] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
91 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
92 Rodriguez‐torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory‐sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study. J Viral Hepat 2016;23:614-22. [DOI: 10.1111/jvh.12527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
93 Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. Journal of Hepatology 2017;66:862-3. [DOI: 10.1016/j.jhep.2017.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
94 Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, Matsumoto N, Okuse C, Itoh F, Yokomaku Y, Watanabe T. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clin J Gastroenterol 2017;10:41-6. [PMID: 27766544 DOI: 10.1007/s12328-016-0693-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Jayasekera CR, Beckerman R, Smith N, Perumpail RB, Wong RJ, Younossi ZM, Ahmed A. Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. J Clin Transl Hepatol 2017;5:16-22. [PMID: 28507921 DOI: 10.14218/JCTH.2016.00052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Suzuki M, Tajiri H, Tanaka Y, Takano T, Miyoshi Y, Murakami J, Shimizu T, Brooks S. Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr 2016;63:88-93. [PMID: 26825765 DOI: 10.1097/MPG.0000000000001120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
97 Cholankeril G, Yoo ER, Hu M, Gadiparthi C, Khan MA, Perumpail RB, Bonham CA, Ahmed A. Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents. J Viral Hepat 2017;24:1194-5. [DOI: 10.1111/jvh.12750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
98 Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiol Genomics 2017;49:567-81. [PMID: 28887371 DOI: 10.1152/physiolgenomics.00035.2017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
99 Pellicelli AM, Pace Palitti V, Vignally P, Ceccherini-Silberstein F, Siciliano M, Giannelli V, Moretti A, Tarquini P, Scifo G, Messina V, Ascione A, Izzi A, Marignani M, D'Ambrosio C, Fondacaro L, Ettorre GM, Ialongo P, Sacco R, Perno CF, Barbarini G; CLEO Group. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver Int 2017;37:653-61. [PMID: 27782373 DOI: 10.1111/liv.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
100 Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67:847-857. [PMID: 29108121 DOI: 10.1002/hep.29642] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
101 Marques S, Carmo J, Túlio MA, Bispo M, Matos L, Chagas C. Diagnostic Performance of Real-Time Elastography in the Assessment of Advanced Fibrosis in Chronic Hepatitis C. GE Port J Gastroenterol 2016;23:13-8. [PMID: 28868425 DOI: 10.1016/j.jpge.2015.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
102 Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuaillon E, van de Perre P, Pichler C, Denkinger CM, Easterbrook P. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis 2017;17:693. [PMID: 29143616 DOI: 10.1186/s12879-017-2776-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
103 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24. [PMID: 27186235 DOI: 10.1186/s13027-016-0071-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
105 Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis 2020;70:2355-65. [PMID: 31513710 DOI: 10.1093/cid/ciz696] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
106 Castro R, Perazzo H, Grinsztejn B, Veloso VG, Hyde C. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol. 2015;2015:852968. [PMID: 26693356 DOI: 10.1155/2015/852968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
107 Ballester-Ferré MP, Martínez F, Garcia-Gimeno N, Mora F, Serra MA. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World J Hepatol 2017; 9(3): 161-166 [PMID: 28217253 DOI: 10.4254/wjh.v9.i3.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
108 Chan PL, Le LV, Ishikawa N, Easterbrook P. Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020. Glob Health Med 2021;3:253-61. [PMID: 34782866 DOI: 10.35772/ghm.2021.01065] [Reference Citation Analysis]
109 Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016;64:301-7. [PMID: 26476290 DOI: 10.1016/j.jhep.2015.10.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 16.0] [Reference Citation Analysis]
110 Chaabna K, Dashzeveg D, Shagdarsuren T, Al-Rifai RH. Prevalence and genotype distribution of hepatitis C virus in Mongolia: Systematic review and meta-analysis. Int J Infect Dis 2021;105:377-88. [PMID: 33601031 DOI: 10.1016/j.ijid.2021.02.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. Biomed Res Int 2017;2017:9849823. [PMID: 29164151 DOI: 10.1155/2017/9849823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
112 Cheng EY, Saab S, Holt CD, Busuttil RW. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. Expert Opinion on Pharmacotherapy 2015;16:2835-48. [DOI: 10.1517/14656566.2015.1114099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
113 Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS. Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis 2017;4:ofx024. [PMID: 28480293 DOI: 10.1093/ofid/ofx024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
114 Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-silberstein F. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother 2016;71:739-50. [DOI: 10.1093/jac/dkv403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
115 Ji F, Wang W, Dang S, Wang S, Li B, Bai D, Zhao W, Deng H, Tian C, Li Z. Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study. Infect Agent Cancer. 2017;12:48. [PMID: 28924449 DOI: 10.1186/s13027-017-0158-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
116 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
117 de la Calle-Prieto F, Martín-Quirós A, Trigo E, Mora-Rillo M, Arsuaga M, Díaz-Menéndez M, Arribas JR. Therapeutic management of Crimean-Congo haemorrhagic fever. Enferm Infecc Microbiol Clin (Engl Ed) 2018;36:517-22. [PMID: 28669587 DOI: 10.1016/j.eimc.2017.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
118 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
119 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
120 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Johnson K, Green PK, Ioannou GN. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. J Viral Hepat 2017;24:966-75. [PMID: 28585416 DOI: 10.1111/jvh.12731] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
122 Akar T. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C? Rev Assoc Med Bras (1992) 2018;64:224-9. [PMID: 29641775 DOI: 10.1590/1806-9282.64.03.224] [Reference Citation Analysis]
123 O'Brien TR, Feld JJ, Kottilil S, Pfeiffer RM. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology 2016;63:28-30. [PMID: 26474163 DOI: 10.1002/hep.28292] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
124 Lobato CMO, Balassiano N, Hyppolito EB, Sanchez-Lermen RLP, Signorelli IV, Nicacio MYT, Firmino Filho AP, Andrade TG, Lima JMC, Arruda TA, Coutinho FS, Araujo EFDV, Esmeraldo TM, Cortez E, Capeli RLA, Matos MBM, Pessoa FSR, Oliveira HC, Arruda ÉAG, Gonçalves PL, Araújo Filho AH, Esberard EBC, Souto FJD. Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. Rev Soc Bras Med Trop 2018;51:14-20. [PMID: 29513836 DOI: 10.1590/0037-8682-0279-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Kang HJ, Lee JY, Lee KB, Joo I, Suh KS, Lee HK, Han JK. Addition of Reliability Measurement Index to Point Shear Wave Elastography: Prospective Validation via Diagnostic Performance and Reproducibility. Ultrasound Med Biol 2019;45:1594-602. [PMID: 31031036 DOI: 10.1016/j.ultrasmedbio.2019.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Chua JV, Ntem-Mensah A, Abutaleb A, Husson J, Mutumbi L, Lam KW, Ghosh A, Romani S, Poonia B, Lee S, Luz Pascual M, Frumkin LR, Kottilil S. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. J Med Virol 2021;93:3752-60. [PMID: 33150966 DOI: 10.1002/jmv.26652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T, Stättermayer AF, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS 2016;30:1039-47. [PMID: 26760453 DOI: 10.1097/QAD.0000000000001020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
128 Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol 2018;45:1426-39. [PMID: 30173152 DOI: 10.3899/jrheum.171459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
129 Teng W, Hsieh YC, Lui KW, Chen WT, Hung CF, Huang CH, Chen YC, Jeng WJ, Lin CC, Lin CY, Lin SM, Sheen IS. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Viral Hepat 2017;24:1160-7. [PMID: 28643457 DOI: 10.1111/jvh.12745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
130 Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
131 Feld JJ. Resistance testing: Interpretation and incorporation into HCV treatment algorithms. Clin Liver Dis (Hoboken) 2017;9:115-20. [PMID: 30992973 DOI: 10.1002/cld.631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
132 Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22 Suppl 6:e25348. [PMID: 31468692 DOI: 10.1002/jia2.25348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
133 Fayek SA, Quintini C, Chavin KD, Marsh CL. The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council. Am J Transplant 2016;16:3093-104. [PMID: 27545282 DOI: 10.1111/ajt.14017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
134 Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. J Pediatr Hematol Oncol. 2018;40:511-514. [PMID: 29771862 DOI: 10.1097/mph.0000000000001217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
135 Salek TP, Katz AR, Lenze SM, Lusk HM, Li D, Des Jarlais DC. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW). Int J Drug Policy 2017;48:34-43. [PMID: 28779632 DOI: 10.1016/j.drugpo.2017.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
136 John JJ, Sterling RK. Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future? ACG Case Rep J 2021;8:e00581. [PMID: 34007857 DOI: 10.14309/crj.0000000000000581] [Reference Citation Analysis]
137 Werner JM, Vermehren J. New HCV Therapies and Liver Transplantation. Transplantation 2016;100:260-1. [PMID: 26813409 DOI: 10.1097/TP.0000000000001092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Sharma S, Mukherjee D, Nair RK, Datt B, Rao A. Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients. J Transplant 2018;2018:7579689. [PMID: 29796311 DOI: 10.1155/2018/7579689] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
139 Serfaty L. Follow-up of patients with chronic hepatitis C and a sustained viral response. Liver Int. 2016;36 Suppl 1:67-71. [PMID: 26725900 DOI: 10.1111/liv.13016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
140 Nannetti G, Messa L, Celegato M, Pagni S, Basso M, Parisi SG, Palù G, Loregian A. Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2017;134:275-81. [DOI: 10.1016/j.jpba.2016.11.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
141 Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016;41:478-85. [PMID: 27440554 DOI: 10.1111/jcpt.12426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
142 Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018;97:e0416. [PMID: 29642211 DOI: 10.1097/MD.0000000000010416] [Reference Citation Analysis]
143 Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. J Formos Med Assoc 2019;118:1014-23. [PMID: 30448077 DOI: 10.1016/j.jfma.2018.10.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
144 Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Ann Hepatol 2019;18:137-43. [PMID: 31113582 DOI: 10.5604/01.3001.0012.7905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Loggi E, Vukotic R, Conti F, Gitto S, Andreone P. Gold standard assays for the monitoring of patients with chronic hepatitis C. Future Virology 2018;13:529-37. [DOI: 10.2217/fvl-2018-0032] [Reference Citation Analysis]
146 Alsebaey A, Elhelbawy M, Abdel-Razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Rev Anti Infect Ther. 2019;17:749-754. [PMID: 31393188 DOI: 10.1080/14787210.2019.1653184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
147 Mazur WP. Management of Hepatitis C in Delaware Prisons: : Approaching Microenvironmental Eradication. Dela J Public Health 2019;5:20-7. [PMID: 34467026 DOI: 10.32481/djph.2019.05.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
148 Dirchwolf M, Marciano S, Mauro E, Ruf AE, Rezzonico L, Anders M, Chiodi D, Petta NG, Borzi S, Tanno F, Ridruejo E, Barreyro F, Shulman C, Plaza P, Carbonetti R, Tadey L, Schroder T, Fainboim H. Clinical epidemiology of acute hepatitis C in South America. J Med Virol 2017;89:276-83. [PMID: 27253181 DOI: 10.1002/jmv.24588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Chen M, Ma Y, Chen H, Luo H, Dai J, Song L, Yang C, Mei J, Yang L, Dong L, Jia M, Lu L. Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics. PLoS One 2015;10:e0142543. [PMID: 26562015 DOI: 10.1371/journal.pone.0142543] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
150 Greendyke WG, Pereira MR. Infectious Complications and Vaccinations in the Posttransplant Population. Med Clin North Am 2016;100:587-98. [PMID: 27095647 DOI: 10.1016/j.mcna.2016.01.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
151 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
152 Choi IS, Kim KM, Shim SG. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study. Arab J Gastroenterol 2021;22:23-7. [PMID: 33223391 DOI: 10.1016/j.ajg.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, Alikhani A, Hedayatizadeh Omran A, Saeedi M, Merat S, Wentzel H, Garratt A, Levi J, Simmons B, Hill A, Tirgar Fakheri H. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75:3373-3378. [PMID: 32812025 DOI: 10.1093/jac/dkaa332] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
154 Mcmahon BJ, Townshend-Bulson L, Homan C, Gounder P, Barbour Y, Hewitt A, Bruden D, Espera H, Plotnik J, Gove J, Stevenson TJ, Luna SV, Simons BC. Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care. Clin Infect Dis 2020;70:2005-7. [PMID: 31504307 DOI: 10.1093/cid/ciz832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Dig Liver Dis 2018;50:113-23. [PMID: 29233687 DOI: 10.1016/j.dld.2017.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
156 Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016;65:1094-1103. [PMID: 27520879 DOI: 10.1016/j.jhep.2016.07.042] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
157 Tsai PC, Liu TW, Hsieh MH, Yeh ML, Liang PC, Lin YH, Huang CI, Huang CF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. Kaohsiung J Med Sci 2017;33:44-9. [PMID: 28088273 DOI: 10.1016/j.kjms.2016.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
158 Chen J, Zhang X, Luo H, Wu C, Yu M, Liu D, Xi H, Zhou Y, An Y, Xu X. Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. Oncotarget 2017;8:90916-24. [PMID: 29207613 DOI: 10.18632/oncotarget.18701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
159 Chevaliez S, Pawlotsky J. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. Journal of Hepatology 2018;69:916-26. [DOI: 10.1016/j.jhep.2018.05.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
160 Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, Ward Z, Vickerman P, Hickman M, Dillon JF. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat 2019;26:519-28. [PMID: 30422370 DOI: 10.1111/jvh.13035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
161 Cardoso AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, Moraes-Coelho HS, Villela-Nogueira CA. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP). J Viral Hepat 2018;25:1244-50. [PMID: 29768686 DOI: 10.1111/jvh.12930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
162 Mah Y, Liu C, Chen C, Tseng T, Liu C, Chen P, Chen D, Kao J. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. Journal of the Formosan Medical Association 2016;115:953-60. [DOI: 10.1016/j.jfma.2016.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
163 Shiha G, Soliman R, Mikhail N, Hassan A, Eslam M. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. Liver Int 2021. [PMID: 34174150 DOI: 10.1111/liv.14995] [Reference Citation Analysis]
164 Gupta S, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R, Agarwal A, Ranjan G, Kedia S, Acharya SK, Nayak B, Shalimar. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. J Viral Hepat 2018;25:771-8. [DOI: 10.1111/jvh.12870] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
165 Thongprayoon C, Kaewput W, Sharma K, Wijarnpreecha K, Leeaphorn N, Ungprasert P, Sakhuja A, Cabeza Rivera FH, Cheungpasitporn W. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis. World J Hepatol 2018; 10(2): 337-346 [PMID: 29527269 DOI: 10.4254/wjh.v10.i2.337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
167 Malta F, Gaspareto KV, Lisboa-Neto G, Carrilho FJ, Mendes-Correa MC, Pinho JRR. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect Dis 2017;17:716. [PMID: 29132303 DOI: 10.1186/s12879-017-2817-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
168 Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut Liver 2019;13:191-6. [PMID: 30400729 DOI: 10.5009/gnl18240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Morimoto N, Miura K, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Murayama K, Hirosawa T, Goka R, Kunitomo N, Nakamura H, Sugimoto H, Isoda N, Yamamoto H. Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment. J Rural Med 2019;14:78-86. [PMID: 31191770 DOI: 10.2185/jrm.2993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Ly KN, Kim AA, Drobeniuc J, Kodani M, Montgomery JM, Fields BS, Teshale EH. The Prevalence of Hepatitis C Virus Antibody in HIV-Negative Persons in Kenya, 2007. Am J Trop Med Hyg 2018;98:1876-9. [PMID: 29692313 DOI: 10.4269/ajtmh.17-0830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial 2019;32:127-34. [PMID: 30569604 DOI: 10.1111/sdi.12761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
172 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep 2016;6:34935. [PMID: 27731343 DOI: 10.1038/srep34935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
174 Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, Badia-Aranda E, Arús-Soler E, Barritt AS 4th, Bessone F, Biryukova M, Carrilho FJ, Fernández MC, Dorta Guiridi Z, El Kassas M, Eng-Kiong T, Queiroz Farias A, George J, Gui W, Thurairajah PH, Hsiang JC, Husić-Selimovic A, Isakov V, Karoney M, Kim W, Kluwe J, Kochhar R, Dhaka N, Costa PM, Nabeshima Pharm MA, Ono SK, Reis D, Rodil A, Domech CR, Sáez-Royuela F, Scheurich C, Siow W, Sivac-Burina N, Dos Santos Traquino ES, Some F, Spreckic S, Tan S, Vorobioff J, Wandera A, Wu P, Yacoub M, Yang L, Yu Y, Zahiragic N, Zhang C, Cortez-Pinto H, Bataller R. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol 2019;17:2320-2329.e12. [PMID: 30708110 DOI: 10.1016/j.cgh.2019.01.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
175 Du P, Wang X, Kong L, Riley T 3rd, Jung J. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017. Am J Prev Med 2021;60:285-93. [PMID: 33221144 DOI: 10.1016/j.amepre.2020.08.031] [Reference Citation Analysis]
176 Santoriello D, Pullela NK, Uday KA, Dhupar S, Radhakrishnan J, D'Agati VD, Markowitz GS. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy. Kidney Int Rep 2018;3:985-90. [PMID: 29988995 DOI: 10.1016/j.ekir.2018.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
177 Hamburg-Shields E, Prasad M. Infectious Hepatitis in Pregnancy. Clin Obstet Gynecol 2020;63:175-92. [PMID: 31895116 DOI: 10.1097/GRF.0000000000000512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
179 Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, Chung RT. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47:924-929. [PMID: 26365684 DOI: 10.3109/23744235.2015.1078908] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
180 Ampuero J, Romero-Gómez M. Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics 2016;17:1587-94. [PMID: 27547881 DOI: 10.2217/pgs.16.28] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
181 Busca A, Cattaneo C, De Carolis E, Nadali G, Offidani M, Picardi M, Candoni A, Ceresoli E, Criscuolo M, Delia M, Della Pepa R, Del Principe I, Fanci RR, Farina F, Fracchiolla N, Giordano C, Malagola M, Marchesi F, Piedimonte M, Prezioso L, Quinto AM, Spolzino A, Tisi MC, Trastulli F, Trecarichi EM, Zappasodi P, Tumbarello M, Pagano L; SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie). Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Crit Rev Oncol Hematol 2021;158:103203. [PMID: 33388453 DOI: 10.1016/j.critrevonc.2020.103203] [Reference Citation Analysis]
182 Komolmit P, Charoensuk K, Thanapirom K, Suksawatamnuay S, Thaimai P, Chirathaworn C, Poovorawan Y. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial. PLoS One 2017;12:e0174608. [PMID: 28376103 DOI: 10.1371/journal.pone.0174608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
183 Lo AO, Chan HL, Wong VW, Wong GL. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol 2017;32:1071-8. [PMID: 28449343 DOI: 10.1111/jgh.13638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
184 Abdulsamad M, Ihimoyan A. Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side Effect. Case Reports Hepatol 2016;2016:8627139. [PMID: 28044114 DOI: 10.1155/2016/8627139] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
185 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
186 Dabbous HM, Montasser IF, Sakr MA, Refai R, Sayam M, Abdelmonem A, Sayed H, F Abdelghafar M, Bahaa M, S Elmeteini M. Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? Hepat Mon. 2016;16:e35339. [PMID: 27330537 DOI: 10.5812/hepatmon.35339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
188 Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC). Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016;4:E605-14. [PMID: 28018873 DOI: 10.9778/cmajo.20160008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
189 Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Res 2019;163:149-55. [PMID: 30711416 DOI: 10.1016/j.antiviral.2019.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
190 Rey D, Muret P, Piroth L. Optimum combination therapy regimens for HIV/HCV infection. Expert Rev Anti Infect Ther 2016;14:299-309. [PMID: 26822803 DOI: 10.1586/14787210.2016.1147952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, Sockalingam S, Altenberg J, Powis J. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 2017;47:202-8. [DOI: 10.1016/j.drugpo.2017.05.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 13.6] [Reference Citation Analysis]
192 Chiu C. Cutting-Edge Infectious Disease Diagnostics with CRISPR. Cell Host Microbe 2018;23:702-4. [PMID: 29902435 DOI: 10.1016/j.chom.2018.05.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
193 Cunha-Silva M, Mazo D, Arrelaro R, Vaz N, Rabello M, Lopes T, Corrêa B, Torino AB, Cintra M, Lorena S, Sevá-Pereira T, Almeida J. Hand-foot syndrome due to hepatitis C therapy. Rev Assoc Med Bras (1992) 2018;64:415-9. [PMID: 30304139 DOI: 10.1590/1806-9282.64.05.415] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
194 Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:1684-93. [PMID: 26952020 DOI: 10.1111/jgh.13337] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
195 Laique SN, Vargas HE. Hepatitis C Virus: No Longer a Barrier to Oncology Care. Am J Gastroenterol 2019;114:207-8. [PMID: 30676362 DOI: 10.14309/ajg.0000000000000095] [Reference Citation Analysis]
196 Chen CC, Hsu HT, Chen YL, Chen RC, Wu WP, Chou CT. Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) and Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein (WFA⁺-M2BP) in Patients with Chronic Liver Disease. Med Sci Monit 2019;25:7169-74. [PMID: 31548540 DOI: 10.12659/MSM.916533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
197 Abbas Z, Saad M, Nadeem R, Jawed F, Abbas M. Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
198 Hadžić N, Baumann U, Mckiernan P, Mclin V, Nobili V. Long-term challenges and perspectives of pre-adolescent liver disease. The Lancet Gastroenterology & Hepatology 2017;2:435-45. [DOI: 10.1016/s2468-1253(16)30160-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
199 Fabrazzo M, Zampino R, Vitrone M, Sampogna G, Del Gaudio L, Nunziata D, Agnese S, Santagata A, Durante-Mangoni E, Fiorillo A. Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. Brain Sci 2020;10:E483. [PMID: 32726940 DOI: 10.3390/brainsci10080483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Ikeda H, Watanabe T, Matsumoto N, Hiraishi T, Nakano H, Noguchi Y, Hattori N, Shigefuku R, Yamashita M, Nakahara K, Matsunaga K, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M, Itoh F. Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus. JGH Open 2018;2:87-92. [PMID: 30483569 DOI: 10.1002/jgh3.12052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
201 Chen T, Terrault NA. Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant. 2016;21:111-119. [PMID: 26927201 DOI: 10.1097/mot.0000000000000288] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
202 Giard JM, Terrault NA. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. Clin Gastroenterol Hepatol 2015;13:2002-4. [PMID: 26192143 DOI: 10.1016/j.cgh.2015.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
203 Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? J Hepatol 2015;63:779-82. [PMID: 26254264 DOI: 10.1016/j.jhep.2015.06.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
204 Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018;13:e0202777. [PMID: 30138456 DOI: 10.1371/journal.pone.0202777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
205 Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015; 7(28): 2829-2833 [PMID: 26668694 DOI: 10.4254/wjh.v7.i28.2829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
206 Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, Martínez Echeverría A, Elizalde I, Zozaya JM, Castilla J, San Miguel R. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med 2017;129:476-83. [PMID: 28343408 DOI: 10.1080/00325481.2017.1311197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
207 Saleh MI, Bani Melhim S. A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. J Chemother 2019;31:274-83. [PMID: 31070545 DOI: 10.1080/1120009X.2019.1609739] [Reference Citation Analysis]
208 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
209 Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol 2018;53:679-88. [PMID: 29344726 DOI: 10.1007/s00535-018-1429-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
210 Nafari M, Irani S, Vaziri F, Gharibzadeh S, Sakhaee F, Khazeni M, Kalhor N, Jamnani FR, Siadat SD, Fateh A. Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1. Infect Genet Evol 2018;62:296-303. [PMID: 29715527 DOI: 10.1016/j.meegid.2018.04.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Mera J, Joshi K, Thornton K, Box T, Scott J, Sedillo M, Deming P, David C, Essex W, Manch R, Kohli A. Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives. Open Forum Infect Dis 2019;6:ofz128. [PMID: 31289725 DOI: 10.1093/ofid/ofz128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, Milloy MJ. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. HIV Med 2017;18:647-54. [PMID: 28294492 DOI: 10.1111/hiv.12501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
213 Mak SK, Sin HK, Lo KY, Lo MW, Chan SF, Lo KC, Wong YY, Ho LY, Wong PN, Wong AKM. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up. Clin Exp Nephrol 2017;21:764-70. [PMID: 28083764 DOI: 10.1007/s10157-016-1364-7] [Reference Citation Analysis]
214 Zampino R, Vitrone M, Parrella A, Ragone E, Durante-Mangoni E. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. J Chemother 2018;30:129-30. [PMID: 28925824 DOI: 10.1080/1120009X.2017.1376782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
215 Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transpl Int 2016;29:1257-65. [DOI: 10.1111/tri.12870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
216 Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ, Faraj W. Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. Ann Med Surg (Lond) 2020;57:166-70. [PMID: 32774848 DOI: 10.1016/j.amsu.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Sikavi C, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. Dig Dis Sci 2018;63:2829-39. [PMID: 30094623 DOI: 10.1007/s10620-018-5215-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
218 Burman BE, Bacchetti P, Khalili M. Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. Dig Dis Sci 2016;61:2417-25. [PMID: 27007134 DOI: 10.1007/s10620-016-4119-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis 2016;62:1290-6. [PMID: 26908812 DOI: 10.1093/cid/ciw086] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
220 Liao HT, Tan P, Huang JW, Yuan KF. Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis. Transplant Proc 2017;49:1855-63. [PMID: 28923637 DOI: 10.1016/j.transproceed.2017.04.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
221 Bruno G, Saracino A, Fabrizio C, Scudeller L, Milano E, Dell'Acqua R, Ladisa N, Fasano M, Minniti S, Buccoliero G, Tartaglia A, Giammario A, Milella M, Angarano G. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Int J Antimicrob Agents 2017;49:296-301. [PMID: 28163136 DOI: 10.1016/j.ijantimicag.2016.11.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
222 Bass SB, Jessop A, Maurer L, Gashat M, Al Hajji M, Gutierrez M. Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development. J Health Commun 2018;23:117-27. [PMID: 29252118 DOI: 10.1080/10810730.2017.1414902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
223 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
224 Palombo SB, Wendel EC, Kidd LR, Yazdi F, Naljayan MV. MPGN and mixed cryoglobulinemia in a patient with hepatitis C - new treatment implications and renal outcomes. Clin Nephrol Case Stud 2017;5:66-9. [PMID: 29098140 DOI: 10.5414/CNCS109099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
225 Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC. Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. Hepatology 2019;69:1426-41. [PMID: 30387174 DOI: 10.1002/hep.30342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
226 Lim JK, Flamm SL, Singh S, Falck-Ytter YT; Clinical Guidelines Committee of the American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology. 2017;152:1536-1543. [PMID: 28442119 DOI: 10.1053/j.gastro.2017.03.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 15.0] [Reference Citation Analysis]
227 Khan MQ, Moreno AD, Joseph N, Kim G, Fimmel CJ. Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis. ACG Case Rep J 2017;4:e21. [PMID: 28184378 DOI: 10.14309/crj.2017.21] [Reference Citation Analysis]
228 Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Platt HL. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. J Hepatol 2016;65:1112-9. [PMID: 27542322 DOI: 10.1016/j.jhep.2016.07.050] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
229 De Nicola S, Aghemo A. The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver Int 2016;36:791-3. [DOI: 10.1111/liv.13123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
230 Fedonin GG, Fantin YS, Favorov AV, Shipulin GA, Neverov AD. VirGenA: a reference-based assembler for variable viral genomes. Brief Bioinform 2019;20:15-25. [PMID: 28968771 DOI: 10.1093/bib/bbx079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
231 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
232 Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu M, Plauzolles A, Chiche L, Bourlière M, Abravanel F. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. Journal of Hepatology 2018;68:595-7. [DOI: 10.1016/j.jhep.2017.09.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
233 Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514-528. [PMID: 28105744 DOI: 10.1111/liv.13327] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
234 Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong'o AW, Kizito KW, Mucara EWK, González Diaz CI, Musyoki H, Mundia B, Cherutich P, Nyakowa M, Lizcano J, Chhun N, Kurth A, Akiyama MJ, Waruiru W, Bhattacharjee P, Cleland C, Donchuk D, Luhmann N, Loarec A, Maman D, Walker J, Vickerman P. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction 2021. [PMID: 34184794 DOI: 10.1111/add.15630] [Reference Citation Analysis]
235 Magombedze G, Pasipanodya JG, Gumbo T. Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. Commun Biol 2021;4:664. [PMID: 34079045 DOI: 10.1038/s42003-021-02184-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
236 DeBose-Scarlett A, Balise R, Kwon D, Vadaparampil S, Chen SX, Schiff ER, Ayala GP, Thomas E. Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population. J Transl Med 2018;16:178. [PMID: 29954391 DOI: 10.1186/s12967-018-1555-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
237 Jaruvongvanich V, Sanguankeo A, Klomjit N, Upala S. Effects of caffeine consumption in patients with chronic hepatitis C: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:46-55. [PMID: 27350575 DOI: 10.1016/j.clinre.2016.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
238 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
239 Shin J, Yu JH, Jin YJ, Chae MH, Yoon CH, Lee JW. Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (Baltimore) 2019;98:e18020. [PMID: 31764818 DOI: 10.1097/MD.0000000000018020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Degré D, Sersté T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS One 2017;12:e0170933. [PMID: 28125694 DOI: 10.1371/journal.pone.0170933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
241 Sherbuk JE, McManus KA, Kemp Knick T, Canan CE, Flickinger T, Dillingham R. Disparities in Hepatitis C Linkage to Care in the Direct Acting Antiviral Era: Findings From a Referral Clinic With an Embedded Nurse Navigator Model. Front Public Health 2019;7:362. [PMID: 31828056 DOI: 10.3389/fpubh.2019.00362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
242 Vermehren J, Maasoumy B, Maan R, Cloherty G, Berkowski C, Feld JJ, Cornberg M, Pawlotsky JM, Zeuzem S, Manns MP, Sarrazin C, Wedemeyer H. Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clin Infect Dis 2016;62:1228-34. [PMID: 26908802 DOI: 10.1093/cid/ciw061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
243 El Kassas M, Elbaz T, Elsharkawy A, Omar H, Esmat G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16:345-350. [PMID: 29506418 DOI: 10.1080/14787210.2018.1448709] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
244 Numao H, Shimaya K, Kakuta A, Shibutani K, Igarashi S, Hasui K, Hanabata N, Kanazawa K, Munakata M. The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 2021;33:1400-7. [DOI: 10.1097/meg.0000000000001887] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Saeed N, Gurakar A. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian J Hepatogastroenterol 2016;6:35-42. [PMID: 29201722 DOI: 10.5005/jp-journals-10018-1163] [Reference Citation Analysis]
246 Calner P, Sperring H, Ruiz-Mercado G, Miller NS, Andry C, Battisti L, Scrudder K, Shea F, Chan A, Schechter-Perkins EM. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One 2019;14:e0218388. [PMID: 31291275 DOI: 10.1371/journal.pone.0218388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
247 Li Z, Zhang Y, Liu Y, Shao X, Luo Q, Cai Q, Zhao Z. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. Medicine (Baltimore) 2017;96:e6830. [PMID: 28489763 DOI: 10.1097/MD.0000000000006830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
248 Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
249 Gomide GPM, Melo CB, Santos VDS, Salge VD, Camargo FC, Pereira GA, Cabral SCO, Molina RJ, Oliveira CDCHB. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2019;52:e20190202. [PMID: 31596352 DOI: 10.1590/0037-8682-0202-2019] [Reference Citation Analysis]
250 Gounder PP, Haering C, Bruden DJT, Townshend-Bulson L, Simons BC, Spradling PR, McMahon BJ. Does Incorporating Change in APRI or FIB-4 Indices Over Time Improve the Accuracy of a Single Index for Identifying Liver Fibrosis in Persons With Chronic Hepatitis C Virus Infection? J Clin Gastroenterol 2018;52:60-6. [PMID: 27875352 DOI: 10.1097/MCG.0000000000000753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
251 Lim SG. HCV management in resource-constrained countries. Hepatol Int 2017;11:245-54. [PMID: 28224352 DOI: 10.1007/s12072-017-9787-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
252 Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 2016;1:97-104. [PMID: 27917405 DOI: 10.1016/S2468-1253(16)30015-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
253 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
254 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
255 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol 2016;51:380-9. [DOI: 10.1007/s00535-015-1117-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
256 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
257 Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol 2016;64:763-5. [PMID: 26795828 DOI: 10.1016/j.jhep.2016.01.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
258 Mehta SH, Thomas DL. Doing the math on hepatitis C virus treatment. J Hepatol 2016;65:5-6. [PMID: 27050632 DOI: 10.1016/j.jhep.2016.03.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
259 Lagaye S, Brun S, Gaston J, Shen H, Stranska R, Camus C, Dubray C, Rousseau G, Massault PP, Courcambeck J, Bassisi F, Halfon P, Pol S. Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World J Hepatol 2016; 8(21): 902-914 [PMID: 27478540 DOI: 10.4254/wjh.v8.i21.902] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
260 Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol 2017;2:832-6. [PMID: 28802815 DOI: 10.1016/S2468-1253(17)30053-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
261 Thomas P, Santiago T, Dallas MH. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone Marrow Transplant 2016;51:735-7. [DOI: 10.1038/bmt.2015.309] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
262 Deng G, Ma J, Shen S, Li Q, Peng L, Meng S, Zhou J, Wu J, Liu D. Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report. Transplant Proc 2016;48:3120-2. [PMID: 27932161 DOI: 10.1016/j.transproceed.2016.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
263 Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL;  HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741-747. [PMID: 27388925 DOI: 10.1016/j.jhep.2016.06.019] [Cited by in Crossref: 249] [Cited by in F6Publishing: 229] [Article Influence: 41.5] [Reference Citation Analysis]
264 von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47:1288-1295. [PMID: 29536554 DOI: 10.1111/apt.14592] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
265 Stewart RA, MacDonald BR, Chu TC, Moore JD, Fasanmi EO, Ojha RP. Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. Dig Dis Sci 2018;63:3233-40. [PMID: 30014226 DOI: 10.1007/s10620-018-5205-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
266 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
267 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
268 Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66:1173-1181. [PMID: 28161470 DOI: 10.1016/j.jhep.2017.01.020] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 20.0] [Reference Citation Analysis]
269 AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67:1477-92. [PMID: 30215672 DOI: 10.1093/cid/ciy585] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 92.3] [Reference Citation Analysis]
270 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
271 Tahata Y, Sakamori R, Urabe A, Morishita N, Yamada R, Yakushijin T, Hiramatsu N, Doi Y, Kaneko A, Hagiwara H, Yamada Y, Hijioka T, Inada M, Tamura S, Imai Y, Furuta K, Kodama T, Hikita H, Tatsumi T, Takehara T. Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. Hepatol Commun 2018;2:884-92. [PMID: 30094400 DOI: 10.1002/hep4.1206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
272 Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 2016;63:1479-1481. [PMID: 27553377 DOI: 10.1093/cid/ciw579] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
273 Trivedi HD, Lai M. Editorial: combining elastography with blood test for fibrosis assessment in chronic hepatitis C. Aliment Pharmacol Ther 2017;45:1275-6. [DOI: 10.1111/apt.14011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
274 Choudhary NS, Kumar A, Bodh V, Bansal SB, Sharma R, Jain M, Saigal S, Saraf N. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol 2017;36:113-6. [DOI: 10.1007/s12664-017-0735-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
275 Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. J Gastroenterol. 2018;53:548-556. [PMID: 28815329 DOI: 10.1007/s00535-017-1380-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
276 Braun P, Drago M, Fanti D, Fleury H, Hofmann J, Izopet J, Kühn S, Lombardi A, Micheli V, Sauné K, Trimoulet P, Whittaker D, Artus A, Rhodes D. A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS® TaqMan® HCV Test and RealTime HCV Assay. J Clin Virol 2017;90:18-25. [PMID: 28319847 DOI: 10.1016/j.jcv.2017.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
277 Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. AIDS 2016;30:2085-90. [PMID: 27149089 DOI: 10.1097/QAD.0000000000001143] [Reference Citation Analysis]
278 Reinharz V, Churkin A, Dahari H, Barash D. A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics. Front Appl Math Stat 2017;3:20. [PMID: 30854378 DOI: 10.3389/fams.2017.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
279 Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C. Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. J Infect Chemother. 2018;24:524-530. [PMID: 29628383 DOI: 10.1016/j.jiac.2018.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
280 Yang R, Gao N, Chang Q, Meng X, Wang W. The role of IDO, IL-10, and TGF-β in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 2019;91:265-71. [PMID: 29611873 DOI: 10.1002/jmv.25083] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
281 Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI, Huang JF, Lu SN, Dai CY, Jen CL, Yuan Y, L'Italien G, Wang LY, Lee MH, Yu ML, Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget 2017;8:43925-33. [PMID: 28159934 DOI: 10.18632/oncotarget.14937] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
282 Goel A, Bhadauria DS, Kaul A, Prasad N, Gupta A, Sharma RK, Rai P, Aggarwal R. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis: HCV treatment in patients on dialysis. Nephrology 2017;22:706-11. [DOI: 10.1111/nep.12833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
283 Win NN, Nakamoto S, Kanda T, Takahashi H, Takahashi-Nakaguchi A, Yasui S, Nakamura M, Wu S, Imazeki F, Mikami S, Yokosuka O, Gonoi T, Shirasawa H. Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences. Int J Mol Sci 2017;18:E172. [PMID: 28106726 DOI: 10.3390/ijms18010172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
284 Jessop AB, Bass SB, Brajuha J, Alhajji M, Burke M, Gashat MT, Wellington C, Ventriglia N, Coleman J, D'Avanzo P. "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy. J Subst Abuse Treat 2020;109:23-33. [PMID: 31856947 DOI: 10.1016/j.jsat.2019.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 Chen YC, Li CH, Ko PH, Lee CC, Syu RJ, Tseng CW, Tseng KC. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. PLoS One 2021;16:e0256505. [PMID: 34437608 DOI: 10.1371/journal.pone.0256505] [Reference Citation Analysis]
286 Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans? Clin Mol Hepatol 2018;24:294-6. [PMID: 30200750 DOI: 10.3350/cmh.2018.1009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
287 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
288 Fouad H, El Raziky M, Hassan EM, Aziz GMA, Darweesh SK, Sayed AR. Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity. World J Hepatol 2016; 8(30): 1287-1294 [PMID: 27843539 DOI: 10.4254/wjh.v8.i30.1287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
289 Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38-44. [PMID: 27282879 DOI: 10.1007/s12072-016-9749-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
290 Huang CF, Jang TY, Lu PL, Yu ML. Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report. Medicine (Baltimore) 2016;95:e5304. [PMID: 27893666 DOI: 10.1097/MD.0000000000005304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
291 Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96 [PMID: 30148074 DOI: 10.5500/wjt.v8.i4.84] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
292 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
293 Ciesek S, Proske V, Otto B, Pischke S, Costa R, Lüthgehetmann M, Polywka S, Klempnauer J, Nashan B, Manns MP, von Hahn T, Lohse AW, Wedemeyer H, Mix H, Sterneck M. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis 2016;18:326-32. [PMID: 26988272 DOI: 10.1111/tid.12524] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
294 Pawlotsky J. Avoiding treatment failures associated with HCV resistance. Nat Rev Gastroenterol Hepatol 2015;12:673-4. [DOI: 10.1038/nrgastro.2015.184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
295 Jung YK. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3]. Korean J Gastroenterol 2016;67:132-6. [PMID: 26996182 DOI: 10.4166/kjg.2016.67.3.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
296 Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67:1010-1017. [PMID: 29566246 DOI: 10.1093/cid/ciy220] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 24.3] [Reference Citation Analysis]
297 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C. Clin Exp Hepatol 2017;3:198-202. [PMID: 29255808 DOI: 10.5114/ceh.2017.71337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
298 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
299 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
300 Behzadifar M, Azari S, Gorji HA, Rezapour A, Bragazzi NL. The challenges of hepatitis C management in Iran: A qualitative study with patients. Int J Health Plann Manage 2020;35:e56-65. [PMID: 31679166 DOI: 10.1002/hpm.2927] [Reference Citation Analysis]
301 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
302 Wu KL, Chen YL, Ko CJ, Lin PY, Chou CT. Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin-positive Mac-2-binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease. Exp Ther Med 2020;20:1953-60. [PMID: 32782504 DOI: 10.3892/etm.2020.8922] [Reference Citation Analysis]
303 Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. Korean J Intern Med 2021;36:544-56. [PMID: 30879288 DOI: 10.3904/kjim.2018.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
304 Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018;35:843-57. [PMID: 30084012 DOI: 10.1007/s40266-018-0572-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Meng P, Zhao S, Niu X, Fu N, Su S, Wang R, Zhang Y, Qiao L, Nan Y. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses. Int J Mol Sci 2016;17:E1070. [PMID: 27428948 DOI: 10.3390/ijms17071070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
306 Muga R, Sanvisens A, Jarrin I, Fuster D, Bolao F, Tor J, Muñoz A. Hepatitis C infection substantially reduces survival of alcohol-dependent patients. Clin Epidemiol 2018;10:897-905. [PMID: 30123002 DOI: 10.2147/CLEP.S162308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
307 Batsis ID, Wasuwanich P, Karnsakul WW. The management of hepatitis B and hepatitis C in children. Minerva Pediatr 2019;71:59-75. [PMID: 30334626 DOI: 10.23736/S0026-4946.18.05410-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
308 Joglekar K, Eason JD, Molnar MZ. Do we really need more evidence to use hepatitis C positive donor kidney more liberally? Clin Kidney J 2017;10:560-3. [PMID: 28835817 DOI: 10.1093/ckj/sfx067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
309 Butt N, Akbar A, Abbasi A, Reema S, Baqar JB, Shaikh QH. Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience. Cureus 2019;11:e4012. [PMID: 31001466 DOI: 10.7759/cureus.4012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N. Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. Oncotarget 2018;9:16263-70. [PMID: 29662642 DOI: 10.18632/oncotarget.24620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Cooper C. Rapid HCV RNA testing: removing the final obstacle to elimination. Lancet Gastroenterol Hepatol 2017;2:468-9. [PMID: 28442272 DOI: 10.1016/S2468-1253(17)30086-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 He YL, Yang SJ, Hu CH, Dong J, Gao H, Yan TT, Liu JF, Yang Y, Ren DF, Zhu L, Zhao YR, Chen TY. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther 2018;47:526-32. [DOI: 10.1111/apt.14429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
313 Leber B, Balázs I, Horvath A, Posch A, Streit A, Spindelböck W, Feldbacher N, Stiegler P, Stauber RE, Rechberger GN, Kollroser M, Sattler W, Nusshold C, Stadlbauer V. Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection. Transl Res 2021;232:103-14. [PMID: 33352296 DOI: 10.1016/j.trsl.2020.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
314 Haga Y, Kanda T, Yasui S, Nakamura M, Ooka Y, Takahashi K, Wu S, Nakamoto S, Arai M, Chiba T, Maruyama H, Yokosuka O, Takada N, Moriyama M, Imazeki F, Kato N. Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget 2018;9:5509-13. [PMID: 29435197 DOI: 10.18632/oncotarget.23768] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Sarpel D, Baichoo E, Dieterich DT. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 2016;14:511-21. [DOI: 10.1586/14787210.2016.1174066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
316 Funk E, Kottilil S, Gilliam B, Talwani R. Tickling the TLR7 to cure viral hepatitis. J Transl Med 2014;12:129. [PMID: 24884741 DOI: 10.1186/1479-5876-12-129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
317 Sanvisens A, Muñoz A, Bolao F, Zuluaga P, Farré M, Jarrin I, Tor J, Muga R. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder? Drug Alcohol Depend 2018;188:180-6. [PMID: 29778771 DOI: 10.1016/j.drugalcdep.2018.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
318 Yan XB. Anti-HCV therapy: Whether it comes into the age of DAA-based specific therapy? Shijie Huaren Xiaohua Zazhi 2016; 24(13): 1943-1951 [DOI: 10.11569/wcjd.v24.i13.1943] [Reference Citation Analysis]
319 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
320 Nguyen Thi Thu P, Ngo Thi Quynh M, Pham Van L, Nguyen Van H, Nguyen Thanh H, Tsai F. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6054677] [Reference Citation Analysis]
321 Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017;37:5-18. [PMID: 27473533 DOI: 10.1111/liv.13212] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
322 Feng HP, Vaddady P, Guo Z, Liu F, Panebianco D, Levine V, Caro L, Butterton JR, Iwamoto M, Yeh WW. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole. Clin Transl Sci 2017;10:360-5. [PMID: 28625018 DOI: 10.1111/cts.12465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
323 Loggi E, Vukotic R, Andreone P. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options. Expert Rev Anti Infect Ther 2018;16:833-8. [PMID: 30336699 DOI: 10.1080/14787210.2018.1538783] [Reference Citation Analysis]
324 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016;44:400-10. [DOI: 10.1111/apt.13696] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
325 Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147 [PMID: 26839638 DOI: 10.4254/wjh.v8.i3.139] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
326 Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118:556-64. [PMID: 30527566 DOI: 10.1016/j.jfma.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
327 Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis. 2016;63:763-770. [PMID: 27317796 DOI: 10.1093/cid/ciw379] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
328 Murakawa M, Asahina Y, Nagata H, Nakagawa M, Kakinuma S, Nitta S, Kawai-kitahata F, Otani S, Kaneko S, Miyoshi M, Tsunoda T, Asano Y, Sato A, Itsui Y, Azuma S, Nouchi T, Furumoto Y, Asano T, Chuganji Y, Tohda S, Watanabe M. ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin: ITPA variants and SOF/RBV therapy in hepatitis C. Hepatol Res 2017;47:1212-8. [DOI: 10.1111/hepr.12867] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
329 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
330 Doi A, Hikita H, Kai Y, Tahata Y, Saito Y, Nakabori T, Yamada R, Kodama T, Sakamori R, Murayama A, Nitta S, Asahina Y, Suemizu H, Tatsumi T, Kato T, Takehara T. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. J Gastroenterol 2019;54:449-58. [PMID: 30684016 DOI: 10.1007/s00535-018-01541-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
331 Karmarkar T, Padula WV, Gaskin DJ, Watson E, Rodriguez CV. Characteristics associated with time-to-treatment initiation for chronic Hepatitis C with new direct acting antivirals. Pharmacoepidemiol Drug Saf 2021;30:86-96. [PMID: 33090666 DOI: 10.1002/pds.5138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Ho CM, Lee PH, Cheng WT, Hu RH, Wu YM, Ho MC. Succinct guide to liver transplantation for medical students. Ann Med Surg (Lond) 2016;12:47-53. [PMID: 27895907 DOI: 10.1016/j.amsu.2016.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Xu L, Lu W, Li P, Shen F, Mi Y, Fan J. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Digestive and Liver Disease 2017;49:910-7. [DOI: 10.1016/j.dld.2017.03.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
334 Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. J Med Virol 2018;90:919-25. [PMID: 29315652 DOI: 10.1002/jmv.25023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
335 Bischoff J, Rockstroh JK. Are there any challenges left in hepatitis C virus therapy of HIV-infected patients? International Journal of Antimicrobial Agents 2020;56:105527. [DOI: 10.1016/j.ijantimicag.2018.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
336 Perpiñán E, Pérez-Del-Pulgar S, Londoño MC, Mariño Z, Bartres C, González P, García-López M, Pose E, Lens S, Maini MK, Forns X, Koutsoudakis G. Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. Front Immunol 2020;11:129. [PMID: 32161581 DOI: 10.3389/fimmu.2020.00129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
337 Yang R, Yang X, Xiu B, Rao H, Fei R, Guan W, Liu Y, Wang Q, Feng X, Zhang H, Wei L. Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay. J Clin Lab Anal 2017;31. [PMID: 27292225 DOI: 10.1002/jcla.22014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
338 Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol 2018;68:940-8. [PMID: 29288753 DOI: 10.1016/j.jhep.2017.12.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
339 Petitclerc L, Sebastiani G, Gilbert G, Cloutier G, Tang A. Liver fibrosis: Review of current imaging and MRI quantification techniques. J Magn Reson Imaging. 2017;45:1276-1295. [PMID: 27981751 DOI: 10.1002/jmri.25550] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
340 Giuffrè M, Fouraki S, Campigotto M, Colombo A, Visintin A, Buonocore MR, Aversano A, Budel M, Tinè F, Abazia C, Masutti F, Crocè LS. Alanine aminotransferase and spleno-portal dynamics affect spleen stiffness measured by point shear-wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis. J Ultrasound 2021;24:67-73. [PMID: 32304009 DOI: 10.1007/s40477-020-00456-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
341 Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PLoS One 2017;12:e0177323. [PMID: 28557994 DOI: 10.1371/journal.pone.0177323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
342 Carey KJ, Huang W, Linas BP, Tsui JI. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat 2016;66:54-9. [PMID: 26988423 DOI: 10.1016/j.jsat.2016.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
343 Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. Eur J Drug Metab Pharmacokinet 2018;43:81-90. [PMID: 28688001 DOI: 10.1007/s13318-017-0428-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
344 Lin TY, Yeh ML, Huang CI, Chen YL, Dai CY, Huang JF, Lin ZY, Chen SC, Huang CF, Yu ML, Chuang WL. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. Kaohsiung J Med Sci 2017;33:284-9. [PMID: 28601232 DOI: 10.1016/j.kjms.2017.03.007] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
345 Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PLoS One 2019;14:e0218759. [PMID: 31437170 DOI: 10.1371/journal.pone.0218759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
346 Shoreibah M, Orr J, Jones D, Zhang J, Venkata K, Massoud O. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. Hepatol Int 2017;11:434-9. [PMID: 28083718 DOI: 10.1007/s12072-016-9778-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
347 Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016;150:419-429. [PMID: 26497081 DOI: 10.1053/j.gastro.2015.10.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
348 Backstedt D, Pedersen M, Choi M, Seetharam A. 25-Vitamin D levels in chronic hepatitis C infection: association with cirrhosis and sustained virologic response. Ann Gastroenterol. 2017;30:344-348. [PMID: 28469365 DOI: 10.20524/aog.2017.0120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
349 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
350 Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londoño MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2017;2:585-94. [PMID: 28576451 DOI: 10.1016/S2468-1253(17)30116-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
351 Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int 2017;114:597-602. [PMID: 28927498 DOI: 10.3238/arztebl.2017.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
352 Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol 2017;16:215-20. [PMID: 31153414 DOI: 10.5604/16652681.1231581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
353 Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? J Clin Gastroenterol 2020;54:192-9. [PMID: 30789853 DOI: 10.1097/MCG.0000000000001189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
354 Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, Dametto E, Rizzetto M, Salizzoni M, Amoroso A. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016;29:1070-84. [DOI: 10.1111/tri.12795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
355 Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol 2019;19:63. [PMID: 31029101 DOI: 10.1186/s12876-019-0973-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
356 Zubkin ML, Chervinko VI, Ovchinnikov YV, Kryukov EV, Kotenko ON. [Chronic HCV infection: An internist's opinion (Part 2)]. Ter Arkh 2016;88:138-48. [PMID: 28635834 DOI: 10.17116/terarkh20168811138-148] [Reference Citation Analysis]
357 Haq SA, Pagnoux C. Infection-associated vasculitides. Int J Rheum Dis 2019;22 Suppl 1:109-15. [PMID: 29624865 DOI: 10.1111/1756-185X.13287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
358 Zheng F, Xu N, Zhang Y. TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response. Inflammation 2019;42:1317-25. [PMID: 30847745 DOI: 10.1007/s10753-019-00992-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
359 Alroy-Preis S, Daly ER, Adamski C, Dionne-Odom J, Talbot EA, Gao F, Cavallo SJ, Hansen K, Mahoney JC, Metcalf E, Loring C, Bean C, Drobeniuc J, Xia GL, Kamili S, Montero JT; New Hampshire and Centers for Disease Control and Prevention Investigation Teams. Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician. Clin Infect Dis 2018;67:845-53. [PMID: 29767683 DOI: 10.1093/cid/ciy193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
360 Saab S, Challita Y, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo FA, El-Kabany MM, Han SB, Grotts J, Agopian VG, Busuttil RW. Elimination of Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol 2018;6:247-50. [PMID: 30271735 DOI: 10.14218/JCTH.2017.00079] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
361 Reinharz V, Churkin A, Lewkiewicz S, Dahari H, Barash D. A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics. Bull Math Biol 2019;81:3675-721. [PMID: 31338739 DOI: 10.1007/s11538-019-00644-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
362 Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy 2015;26:922-35. [PMID: 26077144 DOI: 10.1016/j.drugpo.2015.05.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
363 Liu GY, Tang O, Brotman DJ, Miller ER 3rd, Moliterno AR, Juraschek SP. Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy. PLoS One 2020;15:e0224977. [PMID: 31940353 DOI: 10.1371/journal.pone.0224977] [Reference Citation Analysis]
364 Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW. Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. Eur J Drug Metab Pharmacokinet 2018;43:321-9. [PMID: 29247332 DOI: 10.1007/s13318-017-0451-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
365 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
366 Clement ME, Collins LF, Wilder JM, Mugavero M, Barker T, Naggie S. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. Infect Dis Clin North Am 2018;32:407-23. [PMID: 29778263 DOI: 10.1016/j.idc.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
367 Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190 [PMID: 26839641 DOI: 10.4254/wjh.v8.i3.183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
368 Lai JB, Witt MA, Pauly MP, Ready J, Allerton M, Seo S, Witt DJ. Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System. Drugs 2017;77:313-8. [PMID: 28078644 DOI: 10.1007/s40265-016-0684-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
369 Reinharz V, Dahari H, Barash D. Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics. Math Biosci 2018;300:1-13. [PMID: 29550297 DOI: 10.1016/j.mbs.2018.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
370 Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease: Hepatitis C in renal patients. Hemodialysis International 2018;22:297-307. [DOI: 10.1111/hdi.12672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
371 Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther 2015;9:6083-94. [PMID: 26622169 DOI: 10.2147/DDDT.S80226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
372 Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24:1098-1106. [PMID: 28632923 DOI: 10.1111/jvh.12737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
373 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
374 Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, Aguilera Guirao A, García-samaniego Rey J, Eiros Bouza JM, Luis Calleja Panero J, García F. El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. Enfermedades Infecciosas y Microbiología Clínica 2019;37:231-8. [DOI: 10.1016/j.eimc.2018.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
375 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C: Ombitasvir/paritaprevir/ritonavir for dialysis patients. Hepatol Res 2017;47:1429-37. [DOI: 10.1111/hepr.12910] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
376 Mekky MA, Abdel-Malek MO, Osman HA, Abdel-Aziz EM, Hashim AA, Hetta HF, Morsy KH. Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. Clin Res Hepatol Gastroenterol 2019;43:82-7. [PMID: 30166253 DOI: 10.1016/j.clinre.2018.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
377 Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018;16:1811-1819.e4. [PMID: 29306043 DOI: 10.1016/j.cgh.2017.12.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
378 Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J, Olmedo Martín R. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol 2016; 22(29): 6573-6581 [PMID: 27547001 DOI: 10.3748/wjg.v22.i29.6573] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
379 Hayes CN, Chayama K. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Rev Clin Pharmacol 2017;10:583-94. [PMID: 28374641 DOI: 10.1080/17512433.2017.1313111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
380 Alric L, Besson C, Lapidus N, Jeannel J, Michot JM, Cacoub P, Canioni D, Pol S, Davi F, Rabiega P, Ysebaert L, Bonnet D, Hermine O. Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLoS One 2016;11:e0162965. [PMID: 27749916 DOI: 10.1371/journal.pone.0162965] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
381 Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67:585-602. [PMID: 28323126 DOI: 10.1016/j.jhep.2017.03.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 11.4] [Reference Citation Analysis]
382 McCarty TR, Lim JK. Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opin Pharmacother 2017;18:165-74. [PMID: 28024124 DOI: 10.1080/14656566.2016.1276564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
383 Kliemann DA, Tovo CV, da Veiga ABG, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 2016; 22(40): 8910-8917 [PMID: 27833382 DOI: 10.3748/wjg.v22.i40.8910] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
384 Cottone C, Bhamidimarri KR. Evaluating CKD/ESRD patient with hepatitis C infection: How to interpret diagnostic testing and assess liver injury. Semin Dial 2019;32:119-26. [PMID: 30599462 DOI: 10.1111/sdi.12760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. Am J Gastroenterol 2017;112:1824-31. [PMID: 29087397 DOI: 10.1038/ajg.2017.399] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
386 Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. J Gastroenterol Hepatol. 2016;31:1757-1765. [PMID: 26992248 DOI: 10.1111/jgh.13374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
387 Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66. [PMID: 28061016 DOI: 10.1111/liv.13357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
388 Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med 2016;8:1-8. [PMID: 26889091 DOI: 10.2147/HMER.S96110] [Reference Citation Analysis]
389 Hu C, Yuan G, Liu J, Huang H, Ren Y, Li Y, Chen X, Li W, Wu T, Deng H, Peng Y, Zhang YY, Zhou Y. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Can J Gastroenterol Hepatol 2018;2018:3908767. [PMID: 30538973 DOI: 10.1155/2018/3908767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
390 Ahn SJ, Lee JM, Chang W, Lee SM, Kang HJ, Yang H, Yoon JH, Park SJ, Han JK. Prospective Validation of Intra- and Interobserver Reproducibility of a New Point Shear Wave Elastographic Technique for Assessing Liver Stiffness in Patients with Chronic Liver Disease. Korean J Radiol 2017;18:926-35. [PMID: 29089825 DOI: 10.3348/kjr.2017.18.6.926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
391 Lin CC, Su SH, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin CY, Sheen IS. CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. BMC Gastroenterol 2017;17:169. [PMID: 29284412 DOI: 10.1186/s12876-017-0724-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
392 Gimeno-Ballester V, Buti M, San Miguel R, Riveiro M, Esteban R. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review. J Viral Hepat 2017;24:904-16. [PMID: 27925386 DOI: 10.1111/jvh.12660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
393 Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 217] [Cited by in F6Publishing: 87] [Article Influence: 43.4] [Reference Citation Analysis]
394 Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29. [PMID: 27222662 DOI: 10.1186/s13027-016-0076-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
395 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
396 Sawinski D, Shelton BA, Mehta S, Reed RD, Maclennan PA, Gustafson S, Segev DL, Locke JE. Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. Am J Transplant 2017;17:3114-22. [DOI: 10.1111/ajt.14419] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
397 Dellay B, Sexter A, Wang JH, Hess GP, Ray Kim W, Israni AK. Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. Pharmacotherapy 2019;39:424-32. [PMID: 30779203 DOI: 10.1002/phar.2237] [Reference Citation Analysis]
398 Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydoğdu Ö, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turk J Gastroenterol 2018;29:464-72. [PMID: 30249562 DOI: 10.5152/tjg.2018.16597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
399 Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol 2016;13:338-51. [PMID: 27147491 DOI: 10.1038/nrgastro.2016.60] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 18.2] [Reference Citation Analysis]
400 Sauné K, Abravanel F, Haslé C, Boineau J, Mengelle C, Izopet J. Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. J Clin Virol 2016;84:7-11. [PMID: 27636506 DOI: 10.1016/j.jcv.2016.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
401 Hickman M, Grebely J, Bruneau J, Coffin P, Degenhardt L, Hutchinson S, Larney S, Martin N, Treloar C, Vickerman P. New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series. Addiction 2017;112:1126-7. [PMID: 28586551 DOI: 10.1111/add.13847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
402 Lee HW. Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response. Gut Liver 2016;10:661-2. [PMID: 27563016 DOI: 10.5009/gnl16340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
403 Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33:551-557. [PMID: 29352420 DOI: 10.1007/s11606-017-4280-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
404 Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China. Arch Med Sci 2018;14:1055-60. [PMID: 30154888 DOI: 10.5114/aoms.2017.70664] [Reference Citation Analysis]
405 Vázquez-Morón S, Ryan P, Ardizone-Jiménez B, Martín D, Troya J, Cuevas G, Valencia J, Jimenez-Sousa MA, Avellón A, Resino S. Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Sci Rep 2018;8:1858. [PMID: 29382904 DOI: 10.1038/s41598-018-20312-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
406 Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse? Clin J Gastroenterol 2019;12:598-602. [PMID: 31165460 DOI: 10.1007/s12328-019-01001-w] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
407 Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018;155:1154-1163.e3. [PMID: 30009816 DOI: 10.1053/j.gastro.2018.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 22.5] [Reference Citation Analysis]
408 Lai JB, Witt MA, Pauly MP, Ready J, Allerton M, Seo S, Witt DJ. Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System. Drugs. 2017;77:313-318. [PMID: 28078644 DOI: 10.1007/s40265-016-0684-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
409 Westerhoff M, Ahn J. Chronic Hepatitis C and Direct Acting Antivirals. Surgical Pathology Clinics 2018;11:287-96. [DOI: 10.1016/j.path.2018.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
410 Cotte L, Pugliese P, Valantin MA, Cuzin L, Billaud E, Duvivier C, Naqvi A, Cheret A, Rey D, Pradat P. Hepatitis C treatment initiation in HIV-HCV coinfected patients. BMC Infect Dis. 2016;16:345. [PMID: 27450098 DOI: 10.1186/s12879-016-1681-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
411 Cholongitas E, Pipili C, Papatheodoridis GV. Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. World J Hepatol 2017; 9(4): 180-190 [PMID: 28217256 DOI: 10.4254/wjh.v9.i4.180] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
412 Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017;66:703-710. [PMID: 27923693 DOI: 10.1016/j.jhep.2016.11.022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 10.2] [Reference Citation Analysis]
413 Landaverde C, Wells J, Hamner R, Goldstein JL. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:419-29. [PMID: 26818134 DOI: 10.1586/17474124.2016.1147346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
414 Rodriguez C, Soulier A, Demontant V, Poiteau L, Mercier-Darty M, Bouvier-Alias M, Pawlotsky JM, Chevaliez S. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Sci Rep 2018;8:4180. [PMID: 29520035 DOI: 10.1038/s41598-018-22614-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
415 Bian DD, Zhou HY, Liu S, Liu M, Duan C, Zhang JY, Jiang YY, Wang T, Chen Y, Wang Z, Zheng SJ, Duan ZP. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore) 2017;96:e7885. [PMID: 28834904 DOI: 10.1097/MD.0000000000007885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
416 Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. Sci Rep 2018;8:4619. [PMID: 29545599 DOI: 10.1038/s41598-018-22620-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
417 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
418 Li Y, Huang H, Zabinsky ZB, Liu S. Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections. MDM Policy Pract 2017;2:2381468316686795. [PMID: 30288414 DOI: 10.1177/2381468316686795] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
419 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, Goto H, Hirooka Y. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9:252-256. [PMID: 27329484 DOI: 10.1007/s12328-016-0657-410.1007/s12328-016-0657-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
420 Wiznia LE, Laird ME, Franks AG Jr. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. J Eur Acad Dermatol Venereol. 2017;31:1260-1270. [PMID: 28252812 DOI: 10.1111/jdv.14186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
421 Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl 2020;26:349-58. [PMID: 31610089 DOI: 10.1002/lt.25662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
422 Bruden DJT, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, Homan C, Hewitt A, Barbour Y, Spradling PR, Simons BC, McArdle S, Bruce M. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology 2017;66:37-45. [PMID: 28195349 DOI: 10.1002/hep.29115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
423 Mohamed IEL, El-saeed KM, Al-sadik MH, Anwar CA. Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00089-5] [Reference Citation Analysis]
424 Patiño-Galindo JÁ, Salvatierra K, González-Candelas F, López-Labrador FX. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6. Antimicrob Agents Chemother 2016;60:2402-16. [PMID: 26856832 DOI: 10.1128/AAC.02776-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
425 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
426 Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open 2019;9:e029538. [PMID: 31551376 DOI: 10.1136/bmjopen-2019-029538] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
427 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
428 Li DK, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. In: Law M, editor. Hepatitis C Virus Protocols. New York: Springer; 2019. pp. 3-32. [DOI: 10.1007/978-1-4939-8976-8_1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
429 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
430 Mesquita F, Santos ME, Benzaken A, Corrêa RG, Cattapan E, Sereno LS, Naveira MC. The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health 2016;16:1132. [PMID: 27806712 DOI: 10.1186/s12889-016-3784-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
431 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
432 Kanda T, Nakamoto S, Sasaki R, Nakamura M, Yasui S, Haga Y, Ogasawara S, Tawada A, Arai M, Mikami S. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int J Med Sci. 2016;13:310-315. [PMID: 27076789 DOI: 10.7150/ijms.14953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
433 Allyn PR, O'Malley SM, Ferguson J, Tseng CH, Chew KW, Bhattacharya D. Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 2018;29:334-40. [PMID: 28820346 DOI: 10.1177/0956462417725462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
434 Yoshioka N, Okumura A, Yamamoto Y, Yamaguchi K, Kaga A, Yamada K, Hirosaki T, Ishikawa D, Kunii S, Watanabe K, Utsunomiya S, Hayashi K, Ishigami M, Goto H, Hirooka Y. Promoting notification and linkage of HBs antigen and anti-HCV antibody-positive patients through hospital alert system. BMC Infect Dis 2017;17:330. [PMID: 28482818 DOI: 10.1186/s12879-017-2438-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
435 Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553-561. [PMID: 28634198 DOI: 10.1136/gutjnl-2017-313983] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 13.2] [Reference Citation Analysis]
436 Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res 2017;37:348-53. [PMID: 28777714 DOI: 10.1089/jir.2016.0131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
437 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
438 Ivanics T, Rizzari M, Moonka D, Al-Kurd A, Delvecchio K, Kitajima T, Elsabbagh AM, Collins K, Yoshida A, Abouljoud M, Nagai S. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction. Am J Transplant 2021;21:1100-12. [PMID: 32794649 DOI: 10.1111/ajt.16254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Vázquez-Morón S, Ardizone Jiménez B, Jiménez-Sousa MA, Bellón JM, Ryan P, Resino S. Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. Sci Rep 2019;9:7316. [PMID: 31086259 DOI: 10.1038/s41598-019-41139-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
440 Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int. 2016;36:1793-1799. [PMID: 27254286 DOI: 10.1111/liv.13179] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
441 Na SK, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. J Interferon Cytokine Res. 2019;39:703-710. [PMID: 31216229 DOI: 10.1089/jir.2019.0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
442 Abdulaziz S, Halabi H, Omair MA, Attar S, Alghamdi A, Shabrawishi M, Neyazi A, Alnazzawi H, Meraiani N, Almoallim H. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. Eur J Rheumatol 2017;4:194-9. [PMID: 29164002 DOI: 10.5152/eurjrheum.2017.17003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
443 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
444 Taylor J, Cox-North P, Landis CS. Management of Post-Liver Transplant Recurrence of Hepatitis C. Drugs 2016;76:1711-7. [PMID: 27878476 DOI: 10.1007/s40265-016-0658-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
445 Romagnoli D. Elimination of hepatitis C virus infection in Europe: targeting the obstacles. Exploration of Medicine. [DOI: 10.37349/emed.2022.00075] [Reference Citation Analysis]
446 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Adekunle RO, DeSilva K, Cartwright EJ. Hepatitis C Care Continuum in a Human Immunodeficiency Virus (HIV) Positive Cohort: Data From the HIV Atlanta Veterans Affairs Cohort Study. Open Forum Infect Dis 2020;7:ofaa085. [PMID: 32280724 DOI: 10.1093/ofid/ofaa085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Yang CHT, Yoo ER, Ahmed A. The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. J Clin Transl Hepatol. 2017;5:59-66. [PMID: 28507928 DOI: 10.14218/jcth.2016.00053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
449 Hsu CS, Kao JH. Management of hepatitis C patients with decompensated liver disease. Expert Rev Gastroenterol Hepatol 2016;10:679-88. [PMID: 26782619 DOI: 10.1586/17474124.2016.1143775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
450 Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol 2016;22:432-8. [PMID: 28081594 DOI: 10.3350/cmh.2016.0107] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
451 Wobser H, Paur T, Schnoy E, Hartl J, Kirchner GI. Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. United European Gastroenterol J 2018;6:247-54. [PMID: 29511554 DOI: 10.1177/2050640617711632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
452 Du P, Yin X, Kong L, Jung J. A Telementoring Program and Hepatitis C Virus Care in Rural Patients. Telemed Rep 2021;2:143-7. [PMID: 34041510 DOI: 10.1089/tmr.2021.0001] [Reference Citation Analysis]
453 Puri P, Kumar S. Liver involvement in human immunodeficiency virus infection. Indian J Gastroenterol 2016;35:260-73. [DOI: 10.1007/s12664-016-0666-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
454 Saab S, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. Hepatitis C Virus Prevalence in Egyptian Americans in Southern California. J Clin Gastroenterol 2018;52:55-9. [PMID: 28617761 DOI: 10.1097/MCG.0000000000000858] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
455 Puoti M, Rossotti R, Baiguera C, Orso M. Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? Liver Int 2016;36:181-4. [DOI: 10.1111/liv.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
456 Singal AK, Venkata KVR, Jampana S, Islam FU, Anderson KE. Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda. Am J Med Sci 2017;353:523-8. [PMID: 28641714 DOI: 10.1016/j.amjms.2017.03.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
457 Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep 2016;6:22995. [PMID: 26965318 DOI: 10.1038/srep22995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 La Manna G. HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs). J Nephrol 2018;31:185-7. [PMID: 29411309 DOI: 10.1007/s40620-018-0476-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
459 Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
460 Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. J Gastrointest Cancer 2020;51:584-90. [PMID: 31407252 DOI: 10.1007/s12029-019-00293-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
461 Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, Nair S, Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol 2018; 24(3): 315-322 [PMID: 29391754 DOI: 10.3748/wjg.v24.i3.315] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
462 Naghdi R, Seto K, Klassen C, Emokpare D, Conway B, Kelley M, Yoshida E, Shah HA. A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers. Can J Gastroenterol Hepatol 2017;2017:5324290. [PMID: 28396854 DOI: 10.1155/2017/5324290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
463 Choi MS, Lee K, Hong YJ, Song EY, Kim DS, Song J. The Role of the Signal-to-Cutoff Ratio in Automated Anti-HCV Chemiluminescent Immunoassays by Referring to the Nucleic Acid Amplification Test and the Recombinant Immunoblot Assay. Ann Lab Med 2018;38:466-72. [PMID: 29797818 DOI: 10.3343/alm.2018.38.5.466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
464 Bertino G, Ragusa R, Corsaro LS, Frazzetto E, Messina V, Inguscio L, Lai C, Maglia M, Nunnari A, Caponnetto P. Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). Health Psychol Res 2020;8:9450. [PMID: 33553794 DOI: 10.4081/hpr.2020.9450] [Reference Citation Analysis]
465 Sadeghi S, Davari M, Asli E, Gharibzadeh S, Vaziri F, Jamnani FR, Fateh A, Siadat SD. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin. Gene 2017;630:28-34. [PMID: 28827115 DOI: 10.1016/j.gene.2017.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
466 Hong CM, Liu CJ, Yeh SH, Chen PJ. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. J Formos Med Assoc 2017;116:295-9. [PMID: 28034492 DOI: 10.1016/j.jfma.2016.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
467 Ivanenkov YA, Aladinskiy VA, Bushkov NA, Ayginin AA, Majouga AG, Ivachtchenko AV. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opin Ther Pat 2017;27:401-14. [PMID: 27967269 DOI: 10.1080/13543776.2017.1272573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
468 Beck KR, Kim NJ, Khalili M. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. Ann Hepatol 2018;17:413-8. [PMID: 29735789 DOI: 10.5604/01.3001.0011.7385] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
469 Mitchell RA, Hussaini T, Yau AH, Krajden M, Wright AJ, Scudamore CH, Marquez Azalgara V, Erb SR, Yoshida EM. Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplant Direct 2018;4:e347. [PMID: 29707618 DOI: 10.1097/TXD.0000000000000763] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
470 Yang S, Xing H, Feng S, Ju W, Liu S, Wang X, Ou W, Cheng J, Pan CQ. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. Arch Virol 2018;163:467-73. [PMID: 29143142 DOI: 10.1007/s00705-017-3640-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
471 Chen JH, Zeng Z, Zhang XX, Zhang Y, Zhang RW, Wang S, Wu CH, Yu M, Liu D, Xi HL, Zhou YX, An YY, Xu XY. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World J Gastroenterol 2017; 23(22): 4072-4079 [PMID: 28652660 DOI: 10.3748/wjg.v23.i22.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
472 Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417-426. [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 128] [Article Influence: 28.6] [Reference Citation Analysis]
473 Laurito MP, Silva GF, Cheinquer H, Sharma R, Verna E, Parise ER. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS? Arq Gastroenterol 2018;55:179-83. [PMID: 30043870 DOI: 10.1590/S0004-2803.201800000-32] [Reference Citation Analysis]
474 Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2017;2:494-500. [DOI: 10.1016/s2468-1253(17)30071-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
475 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
476 Ward KM, Falade-Nwulia O, Moon J, Sutcliffe CG, Brinkley S, Haselhuhn T, Katz S, Herne K, Arteaga L, Mehta SH, Latkin C, Brooner RK, Sulkowski MS. A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. Open Forum Infect Dis 2019;6:ofz166. [PMID: 31049365 DOI: 10.1093/ofid/ofz166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
477 Mohammed BS, Derayea SM, Hamad AE. Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma. J Chromatogr Sci 2021;59:576-83. [PMID: 33822903 DOI: 10.1093/chromsci/bmab034] [Reference Citation Analysis]
478 Chan J, Gogela N, Zheng H, Lammert S, Ajayi T, Fricker Z, Kim AY, Robbins GK, Chung RT. Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment. Dig Dis Sci 2018;63:486-92. [PMID: 28887750 DOI: 10.1007/s10620-017-4749-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
479 Fernández-Caballero JA, Alvarez M, Chueca N, Pérez AB, García F. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. PLoS One 2017;12:e0175564. [PMID: 28410425 DOI: 10.1371/journal.pone.0175564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
480 Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209. [PMID: 27384079 DOI: 10.1080/17425255.2016.1209484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
481 Sarwar S, Khan AA. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? Pak J Med Sci 2017;33:37-41. [PMID: 28367169 DOI: 10.12669/pjms.331.12163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
482 Shiha G, Soliman R, Mikhail N, Ibrahim A, Serwah A, Khattab M. Changes in hepatic fibrosis stages after achieving SVR following direct‐acting anti‐viral treatment: a prospective study. GastroHep 2020;2:39-48. [DOI: 10.1002/ygh2.384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
483 Chevaliez S, Dubernet F, Dauvillier C, Hézode C, Pawlotsky JM. The New Aptima HCV Quant Dx Real-time TMA Assay Accurately Quantifies Hepatitis C Virus Genotype 1-6 RNA. J Clin Virol 2017;91:5-11. [PMID: 28380393 DOI: 10.1016/j.jcv.2017.03.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
484 Huang JF, Huang CF, Yeh ML, Dai CY, Yu ML, Chuang WL. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? Expert Rev Anti Infect Ther. 2018;16:907-912. [PMID: 30396303 DOI: 10.1080/14787210.2018.1544492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
485 Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology 2015;149:1345-60. [DOI: 10.1053/j.gastro.2015.08.035] [Cited by in Crossref: 221] [Cited by in F6Publishing: 201] [Article Influence: 31.6] [Reference Citation Analysis]
486 Vargas CL, Espinoza MA, Giglio A, Soza A. Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS One 2015;10:e0141660. [PMID: 26544203 DOI: 10.1371/journal.pone.0141660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
487 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684 [PMID: 33033572 DOI: 10.4254/wjh.v12.i9.672] [Reference Citation Analysis]
488 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
489 Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol 2018;69:1221-30. [PMID: 30098373 DOI: 10.1016/j.jhep.2018.07.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
490 Chamorro-de-Vega E, Gimenez-Manzorro A, Sanjurjo M; GRUVIC Study Group. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Med Clin (Barc) 2018;151:85-6. [PMID: 29295791 DOI: 10.1016/j.medcli.2017.10.041] [Reference Citation Analysis]
491 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
492 Kapila N, Muir AJ. A Big Step Forward in Hepatitis C Screening. Clin Liver Dis (Hoboken) 2020;15:149-52. [PMID: 32395241 DOI: 10.1002/cld.922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
493 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
494 Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection: DAA Reduces Incidence of HCC in Patients With HCV. J Med Virol 2017;89:476-83. [DOI: 10.1002/jmv.24663] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 12.5] [Reference Citation Analysis]
495 El-Guindi MA. Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95. [PMID: 27437184 DOI: 10.5223/pghn.2016.19.2.83] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
496 Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32:1754-1762. [PMID: 28230928 DOI: 10.1111/jgh.13771] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
497 Safadi R, Noviello S, Boparai N, McPhee F. Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir. Clin Case Rep 2016;4:653-6. [PMID: 27386121 DOI: 10.1002/ccr3.581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
498 Zhang B, Nguyen NH, Yee BE, Yip B, Nguyen MH. Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis. BMJ Open Gastroenterol 2015;2:e000057. [PMID: 26629360 DOI: 10.1136/bmjgast-2015-000057] [Reference Citation Analysis]
499 Calabrese MJ, Shaya FT, Barnes VL, Akinwumi A, Temesgen K, Baucom S. Aggregate Trends of Hepatitis C Virus Identification and Treatment in Maryland Corrections Fiscal Years 2012-2016. J Urban Health 2018;95:474-8. [PMID: 29214436 DOI: 10.1007/s11524-017-0206-6] [Reference Citation Analysis]
500 Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809-1816. [PMID: 26853230 DOI: 10.1002/hep.28491] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
501 Alric L, Bonnet D. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection. Expert Opin Pharmacother 2016;17:735-42. [PMID: 26933896 DOI: 10.1517/14656566.2016.1161028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
502 Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int 2016;29:999-1007. [DOI: 10.1111/tri.12799] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
503 Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016;151:70-86. [PMID: 27080301 DOI: 10.1053/j.gastro.2016.04.003] [Cited by in Crossref: 368] [Cited by in F6Publishing: 341] [Article Influence: 61.3] [Reference Citation Analysis]
504 Moon AM, Green PK, Berry K, Ioannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 2017;45:1201-12. [PMID: 28271521 DOI: 10.1111/apt.14021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
505 Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal 2017;31. [PMID: 27735085 DOI: 10.1002/jcla.22063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
506 Schreiner AD, Bian J, Zhang J, Haulsee ZM, Marsden J, Durkalski-Mauldin V, Mauldin PD, Moran WP, Rockey DC. The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care. Am J Med 2020;133:214-221.e1. [PMID: 31369723 DOI: 10.1016/j.amjmed.2019.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
507 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
508 Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell DL, Wilson JA. Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol Hepatol 2016;2016:5743521. [PMID: 27446849 DOI: 10.1155/2016/5743521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
509 Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824-1833. [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 15.5] [Reference Citation Analysis]
510 Shoreibah M, Romano J, Sims OT, Guo Y, Jones D, Venkata K, Kommineni V, Orr J, Fitzmorris P, Massoud OI. Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients. J Clin Transl Hepatol 2018;6:391-5. [PMID: 30637216 DOI: 10.14218/JCTH.2018.00026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
511 Gamal N, Andreone P. Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. Expert Opin Drug Saf 2016;15:549-57. [PMID: 26899025 DOI: 10.1517/14740338.2016.1157163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
512 Gayam V, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati P, Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. Gut Liver 2018;12:694-703. [PMID: 29938459 DOI: 10.5009/gnl18004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
513 Attallah AM, Omran D, Abdelrazek MA, Hassany M, Saif S, Farid A, El Essawey R, Ghaffar MA, Aabdelghany M, Yosry A. IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy. J Genet Eng Biotechnol 2021;19:150. [PMID: 34623551 DOI: 10.1186/s43141-021-00250-y] [Reference Citation Analysis]
514 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Gismondo MR, Hofmann J, Izopet J, Kühn S, Lombardi A, Marcos MA, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes DW. European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay. J Clin Microbiol 2017;55:1186-92. [PMID: 28151405 DOI: 10.1128/JCM.02163-16] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
515 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405-14. [PMID: 27115523 DOI: 10.1002/hep.28625] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 24.7] [Reference Citation Analysis]
516 Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 2017;37:369-76. [PMID: 27678216 DOI: 10.1111/liv.13256] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 21.5] [Reference Citation Analysis]
517 Ducancelle A, Leroy V, Vergniol J, Sturm N, Le Bail B, Zarski JP, Nguyen Khac E, Salmon D, de Ledinghen V, Calès P. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. Journal of Clinical Gastroenterology 2017;51:639-49. [DOI: 10.1097/mcg.0000000000000788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 3.4] [Reference Citation Analysis]
518 Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis. 2016;62:1497-1504. [PMID: 26936665 DOI: 10.1093/cid/ciw119] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
519 Pena DZ, Anadão MF, Flores EF, Okada MN, Filho AMP, Ferro RS, Prestes-Carneiro LE. Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil. Microorganisms 2020;8:E1575. [PMID: 33066136 DOI: 10.3390/microorganisms8101575] [Reference Citation Analysis]
520 Lu Y, Yang X, Zhang L. Domain I of hepatitis C virus NS5A associates with ACBD3 in a genotype-dependent manner. Microbiol Immunol 2020;64:574-7. [PMID: 32108375 DOI: 10.1111/1348-0421.12784] [Reference Citation Analysis]
521 Ahmed H, Abushouk AI, Attia A, Gadelkarim M, Gabr M, Negida A, Abdel-daim MM. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis. Journal of Infection and Public Health 2018;11:156-64. [DOI: 10.1016/j.jiph.2017.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
522 Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748. [PMID: 33793594 DOI: 10.1371/journal.pone.0248748] [Reference Citation Analysis]
523 Wadhera V, Harimoto N, Lubezky N, Gomatos I, Facciuto M, Gonzalez D, Stueck A, Fiel MI, Schiano T, Facciuto ME. The impact of donor liver allograft fibrosis on patients undergoing liver transplantation. Clin Transplant 2018;32:e13187. [PMID: 29314293 DOI: 10.1111/ctr.13187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
524 Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology. 2015;62:1871-1882. [PMID: 26340591 DOI: 10.1002/hep.28150] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
525 Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology 2018;67:2449-59. [PMID: 29181853 DOI: 10.1002/hep.29685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
526 Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS study Group. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"? J Infect 2017;75:234-41. [PMID: 28579302 DOI: 10.1016/j.jinf.2017.05.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
527 Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. Sci Rep 2018;8:4619. [PMID: 29545599 DOI: 10.1038/s41598-018-22620-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
528 Ueda Y, Ikegami T, Akamatsu N, Soyama A, Shinoda M, Goto R, Okajima H, Yoshizumi T, Taketomi A, Kitagawa Y, Eguchi S, Kokudo N, Uemoto S, Maehara Y. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol 2017;52:986-91. [PMID: 28138756 DOI: 10.1007/s00535-017-1310-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
529 Alexander LF, Harri P, Little B, Moreno CC, Mittal PK. Magnetic Resonance Imaging of Primary Hepatic Malignancies in Patients With and Without Chronic Liver Disease: A Pictorial Review. Cureus 2017;9:e1539. [PMID: 28989828 DOI: 10.7759/cureus.1539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
530 Asselah T, Thompson AJ, Flisiak R, Romero-Gomez M, Messinger D, Bakalos G, Shiffman ML. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. PLoS One 2016;11:e0150569. [PMID: 26991780 DOI: 10.1371/journal.pone.0150569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
531 Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat 2019;26:675-84. [PMID: 30739366 DOI: 10.1111/jvh.13079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
532 Scott RA, Aithal GP, Francis ST, Irving WL. Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. Gastroenterology 2018;154:1848-50. [DOI: 10.1053/j.gastro.2017.12.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Shah ND, Fried MW. Treatment options of patients with chronic hepatitis C who have failed prior therapy. Clin Liver Dis (Hoboken) 2016;7:40-4. [PMID: 31041026 DOI: 10.1002/cld.532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
534 Cheng PN, Chiu YC, Chiu HC, Chien SC. The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program. Medicine (Baltimore) 2016;95:e3193. [PMID: 27015215 DOI: 10.1097/MD.0000000000003193] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
535 Çiftçibaşı Örmeci A, Yıldız Ç, Saberi B, Gürakar M, Şimşek C, Gürakar A. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature. Turk J Gastroenterol 2019;30:771-5. [PMID: 31530520 DOI: 10.5152/tjg.2019.18656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
536 Chen YP, Cheng H, Rui HL, Dong HR. Cryoglobulinemic vasculitis and glomerulonephritis: concerns in clinical practice. Chin Med J (Engl) 2019;132:1723-32. [PMID: 31283654 DOI: 10.1097/CM9.0000000000000325] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
537 Ferreira VL, Leonart LP, Tonin FS, Borba HHL, Pontarolo R. Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies. Clin Drug Investig 2018;38:389-400. [PMID: 29435907 DOI: 10.1007/s40261-018-0624-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
538 Fisher KA, Cahill LM, Broyles S, Rorke M, Robinson WT. Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use. PLoS One 2018;13:e0196157. [PMID: 29702681 DOI: 10.1371/journal.pone.0196157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
539 Alboraie M, Schütte K, Khairy M, Elsharkawy M, Asem N, Elghamry F, Shalaby H, Esmat G, Malfertheiner P. Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C. Saudi Med J 2017;38:1137-42. [PMID: 29114703 DOI: 10.15537/smj.2017.11.21220] [Reference Citation Analysis]
540 Goel A, Bhadauria DS, Kaul A, Prasad N, Gupta A, Sharma RK, Rai P, Aggarwal R. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol 2017;36:137-40. [PMID: 28345112 DOI: 10.1007/s12664-017-0745-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
541 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
542 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:1028-38. [PMID: 26282715 DOI: 10.1016/j.drugpo.2015.07.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 18.1] [Reference Citation Analysis]
543 Lee HW, Yoo KY, Won JW, Kim HJ. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut Liver 2017;11:721-7. [PMID: 28874040 DOI: 10.5009/gnl17209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
544 Dresch KF, Mattos AA, Tovo CV, Onofrio FQ, Casagrande L, Feltrin AA, Barros IC, Almeida PR. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Rev Inst Med Trop Sao Paulo 2016;58:37. [PMID: 27253739 DOI: 10.1590/S1678-9946201658037] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
545 Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-297. [PMID: 27908905 DOI: 10.2215/cjn.07940716] [Cited by in Crossref: 86] [Cited by in F6Publishing: 31] [Article Influence: 14.3] [Reference Citation Analysis]
546 Wei MT, Le MH, Landis C, Trinh H, Wong G, Le A, Zhang J, Cheung R, Nguyen MH. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. J Med Virol 2021. [PMID: 34219250 DOI: 10.1002/jmv.27168] [Reference Citation Analysis]
547 Vargas C, Espinoza MA, Giglio A, Soza A. Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno. Value Health Reg Issues 2017;14:28-32. [PMID: 29254538 DOI: 10.1016/j.vhri.2017.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
548 Haridy J, Wigg A, Muller K, Ramachandran J, Tilley E, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd M, Chinnaratha MA, Harding D, Ralton L, Colman A, Liew D, Iyngkaran G, Tse E; the Adelaide Liver Group. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. J Viral Hepat 2018;25:1287-97. [DOI: 10.1111/jvh.12943] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
549 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
550 Tokushima Y, Tago M, Tokushima M, Katsuki NE, Iwane S, Eguchi Y, Yamashita SI. Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. Int J Gen Med 2020;13:743-50. [PMID: 33061544 DOI: 10.2147/IJGM.S268857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Macías J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, Pineda JA. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med 2017;18:445-51. [PMID: 27882706 DOI: 10.1111/hiv.12471] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
552 Goolsby Hunter A, Rosenblatt L, Patel C, Blauer-Peterson C, Anduze-Faris B. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype. Curr Med Res Opin 2017;33:829-36. [PMID: 28128648 DOI: 10.1080/03007995.2017.1288613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
553 Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, Vázquez-Morón S, Resino S. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. J Transl Med 2015;13:320. [PMID: 26438033 DOI: 10.1186/s12967-015-0682-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
554 Bragg DA, Crowl A, Manlove E. Hepatitis C: A New Era. Prim Care 2017;44:631-42. [PMID: 29132525 DOI: 10.1016/j.pop.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
555 Deuffic-burban S, Obach D, Canva V, Pol S, Roudot-thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat 2016;23:767-79. [DOI: 10.1111/jvh.12546] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
556 Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Pharmacotherapy. 2016;36:e148-e153. [PMID: 27459733 DOI: 10.1002/phar.1803] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
557 Hézode C, Colombo M, Bourlière M, Spengler U, Ben-ari Z, Strasser SI, Lee WM, Morgan L, Qiu J, Hwang P, Robertson M, Nguyen B, Barr E, Wahl J, Haber B, Chase R, Talwani R, Di Marco V; on behalf of the C-EDGE IBLD Study Investigators. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study: Hézode et al. Hepatology 2017;66:736-45. [DOI: 10.1002/hep.29139] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
558 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
559 Sangaramoorthy M, Yang J, DeRouen MC, Ho C, Somsouk M, Tana MM, Thompson CA, Gibbons J, Gomez SL, Shariff-Marco S. Disparities in Hepatocellular Carcinoma Incidence in California: An Update. Cancer Epidemiol Biomarkers Prev 2020;29:79-87. [PMID: 31719066 DOI: 10.1158/1055-9965.EPI-19-0560] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
560 Sarpel D, Dieterich DT. C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients. Ann Transl Med 2016;4:S12. [PMID: 27867980 DOI: 10.21037/atm.2016.09.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
561 Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;47:1705-1712. [PMID: 29722439 DOI: 10.1111/apt.14685] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
562 Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614-625. [PMID: 28232372 DOI: 10.3324/haematol.2016.150250] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
563 Aoufi-Rabih S, García-Agudo R, Londoño MC, Fraga-Fuentes MD, Barril-Cuadrado G; On behalf on the Spanish Association of the Liver and the Kidney (AEHR). Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. J Nephrol 2018;31:1-13. [PMID: 29064081 DOI: 10.1007/s40620-017-0446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
564 Atsukawa M, Tsubota A. Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia. Aliment Pharmacol Ther 2018;48:770-1. [PMID: 30246309 DOI: 10.1111/apt.14899] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
565 Vitrone M, Parrella A, Albisinni R, Durante-Mangoni E, Zampino R. Dynamics and management of oral anticoagulant treatment in chronic hepatitis C patients undergoing therapy with direct antiviral agents. J Chemother 2019;31:86-9. [PMID: 30784359 DOI: 10.1080/1120009X.2019.1571661] [Reference Citation Analysis]
566 Reddy S, Sharma RK, Mehrotra S, Prasad N, Gupta A, Kaul A, Singh Bhadauria D. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Clin Kidney J 2018;11:429-33. [PMID: 29942507 DOI: 10.1093/ckj/sfx112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
567 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
568 Martinec O, Huliciak M, Staud F, Cecka F, Vokral I, Cerveny L. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. Antimicrob Agents Chemother 2019;63:e00910-19. [PMID: 31481446 DOI: 10.1128/AAC.00910-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
569 Fletcher GJ, Raghavendran A, Sivakumar J, Samuel P, Abraham P. Diagnostic reliability of Architect anti-HCV assay: Experience of a tertiary care hospital in India. J Clin Lab Anal 2018;32. [PMID: 28657153 DOI: 10.1002/jcla.22245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
570 Patra T, Ray RB, Ray R. Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus. Cells 2019;8:E274. [PMID: 30909456 DOI: 10.3390/cells8030274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
571 Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol. 2016;16:73. [PMID: 27457659 DOI: 10.1186/s12876-016-0492-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
572 Cheung A, Levitsky J. Follow-up of the Post-Liver Transplantation Patient: A Primer for the Practicing Gastroenterologist. Clin Liver Dis. 2017;21:793-813. [PMID: 28987263 DOI: 10.1016/j.cld.2017.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
573 Pawlotsky J. Hepatitis C Drugs: Is Next Generation the Last Generation? Gastroenterology 2016;151:587-90. [DOI: 10.1053/j.gastro.2016.08.043] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
574 Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med 2017;15:217. [PMID: 29249202 DOI: 10.1186/s12916-017-0979-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
575 Marshall WL, Feng H, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O’reilly TE, Butterton JR, Yeh WW. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. Eur J Clin Pharmacol 2017;73:593-600. [DOI: 10.1007/s00228-017-2216-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
576 Liao H, Tan P, Zhu Z, Yan X, Huang J. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:262-71. [PMID: 28082137 DOI: 10.1016/j.clinre.2016.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
577 Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 2015;28:576-82. [PMID: 26524330 DOI: 10.1097/QCO.0000000000000216] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 10.2] [Reference Citation Analysis]
578 Nandi P, Kalapila AG, Badell ML, Sheth AN. Sexually acquired acute hepatitis C infection diagnosed during pregnancy: a case report of successful postpartum treatment. Case Rep Womens Health 2018;20:e00080. [PMID: 30364573 DOI: 10.1016/j.crwh.2018.e00080] [Reference Citation Analysis]
579 Quintero J, Juampérez J, Julio E, Cabello V, Mercadal-Hally M, Soler-Palacín P, Segarra Ó, Rodrigo C. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. An Pediatr (Engl Ed) 2019;90:141-7. [PMID: 30126773 DOI: 10.1016/j.anpedi.2018.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
580 Wijarnpreecha K, Thongprayoon C, Ungprasert P. Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:17-22. [PMID: 27676091 DOI: 10.1097/MEG.0000000000000757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
581 Anwar S, Karim MY. Update on systemic vasculitides. J Clin Pathol 2017;70:476-82. [PMID: 28377447 DOI: 10.1136/jclinpath-2016-203875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
582 Flamm S, Peng CY, Shibolet O, Nahass R, Hwang P, Barr E, Robertson MN, Haber BA. Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older. Gerontol Geriatr Med 2019;5:2333721418817398. [PMID: 30891470 DOI: 10.1177/2333721418817398] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
583 Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139-149. [PMID: 27910154 DOI: 10.1111/apt.13844] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
584 Wu J. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget 2016;7:42762-76. [PMID: 27072576 DOI: 10.18632/oncotarget.8641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
585 Facciorusso A, Del Prete V, Turco A, Buccino RV, Nacchiero MC, Muscatiello N. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study. J Gastroenterol Hepatol. 2018;33:942-949. [PMID: 28976021 DOI: 10.1111/jgh.14008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
586 Yaraş S, Üçbilek E, Özdoğan O, Ateş F, Altıntaş E, Sezgin O. Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey. Turk J Gastroenterol 2019;30:331-5. [PMID: 30666967 DOI: 10.5152/tjg.2018.18269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
587 Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018;25 Suppl 1:6-17. [PMID: 29508946 DOI: 10.1111/jvh.12875] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
588 Muna-Aguon P, Ramanathan M, Choi M, Pedersen M, Seetharam A. Lymphovascular invasion on explant is associated with presenting tumor characteristics and not direct acting antiviral utilization in hepatitis C candidates undergoing liver transplantation. Clin Exp Hepatol 2019;5:279-84. [PMID: 31893238 DOI: 10.5114/ceh.2019.88105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
589 Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother 2017;61:e00037-17. [PMID: 28348150 DOI: 10.1128/AAC.00037-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
590 Gray E, Norris S, Schmitz S, O'Leary A. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? J Comp Eff Res 2017;6:65-82. [PMID: 27854129 DOI: 10.2217/cer-2016-0042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
591 Chayama K, Hayes CN. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses. 2015;7:5328-5342. [PMID: 26473914 DOI: 10.3390/v7102876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
592 Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol. 2016;65:S143-S155. [PMID: 27641984 DOI: 10.1016/j.jhep.2016.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
593 Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Ther 2020;37:457-76. [PMID: 31808054 DOI: 10.1007/s12325-019-01166-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
594 Goglin S, Chung SA. Current Treatment of Cryoglobulinemic Vasculitis. Curr Treat Options in Rheum 2016;2:213-24. [DOI: 10.1007/s40674-016-0048-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
595 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:953-60. [PMID: 32376182 DOI: 10.1016/j.jvir.2019.12.809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Kawabe N, Hashimoto S, Yoshioka K. Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. Aliment Pharmacol Ther 2019;49:116-7. [PMID: 30548317 DOI: 10.1111/apt.15051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
597 Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for: Assessments for liver fibrosis. Journal of Gastroenterology and Hepatology 2018;33:1009-15. [DOI: 10.1111/jgh.14103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
598 Cooper C, Naggie S, Saag M, Yang JC, Stamm LM, Dvory-Sobol H, Han L, Pang PS, McHutchison JG, Dieterich D, Sulkowski M. Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. Clin Infect Dis 2016;63:528-31. [PMID: 27225242 DOI: 10.1093/cid/ciw349] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
599 Chen YC, Tseng CW, Tseng KC. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine (Baltimore) 2020;99:e20156. [PMID: 32384505 DOI: 10.1097/MD.0000000000020156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Nguyen P, Vutien P, Hoang J, Trinh S, Le A, Yasukawa LA, Weber S, Henry L, Nguyen MH. Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience. BMJ Open Gastroenterol 2017;4:e000181. [PMID: 29333275 DOI: 10.1136/bmjgast-2017-000181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
601 Rajhi M, Haddad-Boubaker S, Chouikha A, Bourquain D, Michel J, Hammami W, Sadraoui A, Touzi H, Ghedira K, Triki H. Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS One 2021;16:e0248249. [PMID: 33705445 DOI: 10.1371/journal.pone.0248249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
602 Conti F, Serra C, Vukotic R, Fiorini E, Felicani C, Mazzotta E, D'Errico A, Verucchi G, Lenzi M, Andreone P. Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C. Liver Int 2017;37:187-95. [PMID: 27369740 DOI: 10.1111/liv.13197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
603 Cholankeril G, Li AA, March KL, Yoo ER, Kim D, Snyder H, Gonzalez SA, Younossi ZM, Ahmed A. Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol. 2018;16:452-453. [PMID: 28838786 DOI: 10.1016/j.cgh.2017.08.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
604 Hu KQ, Cui W. A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology. 2016;64:415-424. [PMID: 27273268 DOI: 10.1002/hep.28663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
605 Ramesh D, Vijayakumar BG, Kannan T. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 2021;16:1403-19. [PMID: 33427377 DOI: 10.1002/cmdc.202000849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
606 Pérez AB, Chueca N, García F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs 2017;7:40-4. [PMID: 28331841 DOI: 10.18683/germs.2017.1107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
607 Manee N, Thongbaiphet N, Pasomsub E, Chantratita W. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay. J Virol Methods 2017;249:31-7. [PMID: 28851606 DOI: 10.1016/j.jviromet.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
608 Berden FA, de Knegt RJ, Blokzijl H, Kuiken SD, van Erpecum KJ, Willemse SB, den Hollander J, van Vonderen MG, Friederich P, van Hoek B, van Nieuwkerk CM, Drenth JP, Kievit W. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS One 2016;11:e0161821. [PMID: 27598789 DOI: 10.1371/journal.pone.0161821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
609 Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, Shalimar. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. J Clin Exp Hepatol 2019;9:207-14. [PMID: 31024203 DOI: 10.1016/j.jceh.2018.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
610 Przekop D, Klapaczynski J, Grytczuk A, Gruszewska E, Gietka A, Panasiuk A, Golaszewski S, Cylwik B, Chrostek L. Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C. J Clin Med 2021;10:3951. [PMID: 34501398 DOI: 10.3390/jcm10173951] [Reference Citation Analysis]
611 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
612 Yang A, Zachary D, Giang J. Impact of a Nurse Care Coordinator Supporting a Clinical Pharmacist Practitioner in Further Managing HCV-Infected Patients. Gastroenterol Nurs 2021;44:E11-7. [PMID: 33464766 DOI: 10.1097/SGA.0000000000000578] [Reference Citation Analysis]
613 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
614 Parisi SG, Andreis S, Mengoli C, Menegotto N, Cavinato S, Scaggiante R, Andreoni M, Palù G, Basso M, Cattelan AM. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. Med Microbiol Immunol 2018;207:183-94. [PMID: 29523966 DOI: 10.1007/s00430-018-0538-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
615 Ti L, Socías ME, Wood E, Milloy MJ, Nosova E, DeBeck K, Kerr T, Hayashi K. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One 2018;13:e0194162. [PMID: 29579073 DOI: 10.1371/journal.pone.0194162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
616 Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, Abdel-Daim MM. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017;37:1009-23. [PMID: 28871475 DOI: 10.1007/s40261-017-0565-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
617 Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. Antimicrob Agents Chemother 2017;61:e00813-17. [PMID: 28947470 DOI: 10.1128/AAC.00813-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
618 Hatanaka T, Naganuma A, Tateyama Y, Yoshinari F, Hoshino T, Sato K, Hmwe SS, Aizaki H, Wakita T, Kakizaki S, Uraoka T. Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure. Intern Med 2019;58:2969-75. [PMID: 31243225 DOI: 10.2169/internalmedicine.2982-19] [Reference Citation Analysis]
619 Martini S, Salizzoni M, David E, Tandoi F, Fonio P, Delsedime L, Strona S, Dell Olio D, Saracco GM, Romagnoli R. Favorable short-term outcome of hepatitis C virus-positive liver graft with bridging fibrosis: A plea for very early viral eradication. Hepatology 2017;65:2116-8. [PMID: 27981614 DOI: 10.1002/hep.28978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
620 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
621 Owens MD, Ioannou GN, Tsui JL, Edelman EJ, Greene PA, Williams EC. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. Drug Alcohol Depend 2018;188:79-85. [PMID: 29754030 DOI: 10.1016/j.drugalcdep.2018.03.047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
622 Murai K, Shimakami T, Welsch C, Shirasaki T, Liu F, Kitabayashi J, Tanaka S, Funaki M, Omura H, Nishikawa T, Sumiyadorj A, Honda M, Kaneko S. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. Antimicrob Agents Chemother 2018;62:e02601-17. [PMID: 29661883 DOI: 10.1128/AAC.02601-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
623 Morris MD, Mirzazadeh A, Evans JL, Briceno A, Coffin P, Hahn JA, Page KA. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated. Drug Alcohol Depend 2019;198:133-5. [PMID: 30921649 DOI: 10.1016/j.drugalcdep.2019.02.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
624 Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, Laeyendecker O. Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. J Infect Dis 2016;214:344-52. [PMID: 26768250 DOI: 10.1093/infdis/jiw005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
625 Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, Mcginnis J, Saab S, Beckerman R, Younossi ZM. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology 2017;66:46-56. [DOI: 10.1002/hep.29137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
626 Hussein MH, Peedikayil MC, Zamir ZA, Alfadda A. Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents. Ann Thorac Med 2018;13:117-21. [PMID: 29675064 DOI: 10.4103/atm.ATM_194_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
627 Chang PE, Goh GBB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 91-106 [PMID: 26855815 DOI: 10.4292/wjgpt.v7.i1.91] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
628 Li Y, Li L, Liu J, Zhang DW, Zhao F, Wang L, Mahemure A, Xie R, Lei S, Cai W, Wang X, Shu Z, Chen X, Wang H, Wang FS. Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China. Hepatol Int 2018;12:465-73. [PMID: 30203381 DOI: 10.1007/s12072-018-9891-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
629 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
630 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
631 Lee SH, Shin HP, Lee JI. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. Antivir Chem Chemother 2020;28:2040206620974835. [PMID: 33215505 DOI: 10.1177/2040206620974835] [Reference Citation Analysis]
632 Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110. [PMID: 28543053 DOI: 10.1002/hep.29278] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 14.4] [Reference Citation Analysis]
633 Perlman DC, Des Jarlais DC, Feelemyer J. Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis 2015;34:198-205. [PMID: 26075647 DOI: 10.1080/10550887.2015.1059111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
634 Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
635 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
636 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, Goto H, Hirooka Y. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol 2016;9:252-6. [DOI: 10.1007/s12328-016-0657-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
637 Lu M, Li J, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Zhou Y, Boscarino JA, Schmidt MA. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. J Viral Hepat. 2016;23:718-729. [PMID: 27028626 DOI: 10.1111/jvh.12538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
638 Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo A, Gervasoni C, Galli M, Antinori S, Sollima S. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2017;18:284-91. [DOI: 10.1111/hiv.12429] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
639 Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat 2017;24:287-94. [PMID: 27878906 DOI: 10.1111/jvh.12645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
640 Pradat P, Huleux T, Raffi F, Delobel P, Valantin M, Poizot-martin I, Pugliese P, Reynes J, Rey D, Hoen B, Cabie A, Bani-sadr F, Cheret A, Duvivier C, Jacomet C, Fresard A, Hustache-mathieu L, Cotte L. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS 2018;32:1077-82. [DOI: 10.1097/qad.0000000000001789] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
641 Bourgi K, Brar I, Baker-Genaw K. Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. PLoS One 2016;11:e0161241. [PMID: 27525983 DOI: 10.1371/journal.pone.0161241] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
642 Dashti-Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. Expert Rev Clin Pharmacol 2018;11:525-9. [PMID: 29533117 DOI: 10.1080/17512433.2018.1451327] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
643 Alimohammadi A, Hakobyan S, Raycraft T, Vafadary S, Conway B. Evaluation of HCV treatment in people who actively inject drugs. Future Virology 2016;11:483-7. [DOI: 10.2217/fvl-2016-0042] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
644 Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51-56. [PMID: 28983675 DOI: 10.1007/s00705-017-3573-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
645 Evon DM, Golin CE, Ruffin R, Fried MW. Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. Contemp Clin Trials Commun 2017;6:85-96. [PMID: 29082334 DOI: 10.1016/j.conctc.2017.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
646 Athavale AM, Hart PD, Itteera M, Cimbaluk D, Patel T, Alabkaa A, Arruda J, Singh A, Rosenberg A, Kulkarni H. Development and Validation of a Deep Learning Model to Quantify Interstitial Fibrosis and Tubular Atrophy From Kidney Ultrasonography Images. JAMA Netw Open 2021;4:e2111176. [PMID: 34028548 DOI: 10.1001/jamanetworkopen.2021.11176] [Reference Citation Analysis]
647 Aydin Y, Stephens CM, Chava S, Heidari Z, Panigrahi R, Williams DD, Wiltz K, Bell A, Wilson W, Reiss K, Dash S. Chaperone-Mediated Autophagy Promotes Beclin1 Degradation in Persistently Infected Hepatitis C Virus Cell Culture. Am J Pathol. 2018;188:2339-2355. [PMID: 30075149 DOI: 10.1016/j.ajpath.2018.06.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
648 Plant A, Snow EG, Montoya JA, Young S, Javanbakht M, Klausner JD. Test4HepC: Promoting Hepatitis C Testing to Baby Boomers Using Social Media. Health Promot Pract 2020;21:780-90. [PMID: 30854905 DOI: 10.1177/1524839919833987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
649 De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, Cottalorda J, Ollier L, Giordanengo V. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30. [PMID: 26967675 DOI: 10.1016/j.jcv.2016.02.026] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 15.3] [Reference Citation Analysis]
650 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Burrage L, Zimmerman H, Higgins S, Param K, Orme C, Mitchell J, O'Beirne J. Performance of simple serum-based tests to exclude cirrhosis prior to hepatitis C treatment in non-hospital settings in Australia. Intern Med J 2021;51:533-9. [PMID: 31994285 DOI: 10.1111/imj.14767] [Reference Citation Analysis]
652 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 2020;50:892-923. [PMID: 32343469 DOI: 10.1111/hepr.13504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
653 Pruß A, Chandrasekar A, Sánchez-Ibáñez J, Lucas-Samuel S, Kalus U, Rabenau HF. Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus. Transfus Med Hemother 2021;48:12-22. [PMID: 33708048 DOI: 10.1159/000513179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology 2018;67:837-46. [PMID: 29059461 DOI: 10.1002/hep.29611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
655 Calabrese LH, Calabrese C, Kirchner E. The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. Arthritis Care Res (Hoboken) 2016;68:723-4. [PMID: 26866816 DOI: 10.1002/acr.22865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
656 Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, Nair S, Ahmed A. Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. Clin Gastroenterol Hepatol 2019;17:1634-6. [PMID: 30268562 DOI: 10.1016/j.cgh.2018.09.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
657 Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. Int J Mol Sci. 2017;18. [PMID: 28441362 DOI: 10.3390/ijms18050906] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
658 Trémeaux P, Caporossi A, Thélu MA, Blum M, Leroy V, Morand P, Larrat S. Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges. Crit Rev Clin Lab Sci 2016;53:341-51. [PMID: 27068766 DOI: 10.3109/10408363.2016.1163663] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
659 Dhiman RK, Grover GS, Premkumar M, Taneja S, Duseja A, Rathi S, Satsangi S. Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. J Pediatr Gastroenterol Nutr 2019;68:74-80. [PMID: 30211847 DOI: 10.1097/MPG.0000000000002139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
660 Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019;70:839-846. [PMID: 30654067 DOI: 10.1016/j.jhep.2019.01.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
661 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
662 Hsu LI, Wang YH, Hsieh FI, Yang TY, Wen-Juei Jeng R, Liu CT, Chen CL, Hsu KH, Chiou HY, Wu MM, Chen CJ. Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis. Clin Gastroenterol Hepatol 2016;14:1347-1355.e4. [PMID: 27060428 DOI: 10.1016/j.cgh.2016.03.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
663 Janczewska E, Zarębska-Michaluk D, Berak H, Piekarska A, Gietka A, Dybowska D, Mazur W, Belica-Wdowik T, Dobracki W, Tudrujek-Zdunek M, Deroń Z, Buczyńska I, Sitko M, Czauż-Andrzejuk A, Lorenc B, Białkowska-Warzecha J, Citko J, Laurans Ł, Jaroszewicz J, Socha Ł, Tronina O, Adamek B, Horban A, Halota W, Baka-Ćwierz B, Tomasiewicz K, Simon K, Garlicki A, Wawrzynowicz-Syczewska M, Flisiak R. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infect Dis 2018;18:580. [PMID: 30445916 DOI: 10.1186/s12879-018-3465-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
664 Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017;47:1438-1444. [PMID: 28585404 DOI: 10.1111/hepr.12919] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
665 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
666 Aydin Y, Chedid M, Chava S, Danielle Williams D, Liu S, Hagedorn CH, Sumitran-Holgersson S, Reiss K, Moroz K, Lu H, Balart LA, Dash S. Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep 2017;7:9223. [PMID: 28835697 DOI: 10.1038/s41598-017-10087-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
667 Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, Okubo T, Arai T, Itokawa N, Iio E, Tanaka Y, Iwakiri K. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis. 2017;49:1029-1035. [PMID: 28499694 DOI: 10.1016/j.dld.2017.04.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
668 Connolly JC, Lim JK. Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. Curr Hepatology Rep 2019;18:249-58. [DOI: 10.1007/s11901-019-00471-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
669 Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol 2020; 26(38): 5874-5883 [PMID: 33132641 DOI: 10.3748/wjg.v26.i38.5874] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
670 Knight LL, Wagner K, Leyva Y, Bruce VR, White KAM, Talamantes YS, Price B, Page K, Carvour ML. Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs. Health Promot Pract 2018;19:815-22. [PMID: 30227752 DOI: 10.1177/1524839918799455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
671 Makhlouf NA, Farouk M, Nafeh HM, Hasanain AFA, El-mokhtar MA, Hetta HF, Mekky MA, Alboraie M, Elamin H, Nasr AM. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00080-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
672 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017;1:87-98. [PMID: 29404447 DOI: 10.1002/hep4.1028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
673 Dar GA, Yattoo GN, Gulzar GM, Sodhi JS, Gorka S, Laway MA. Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study. J Clin Exp Hepatol 2021;11:227-31. [PMID: 33746448 DOI: 10.1016/j.jceh.2020.06.011] [Reference Citation Analysis